ubc department of medicine page 183 annual report...

UBC DEPARTMENT OF MEDICINE

AWARDS BY DIVISION FOR 2003-2004

Division Researcher Type Award Sponsoring Agency Title

Allergy/Immunology Schellenberg Grant 20,325$ BC Lung: Research Grant (NEW) Effects of Tone on Human Airway Smooth Muscle Contractile Responses: Relevance to Obstructive Lung Disease.

Allergy/Immunology Stark Clinical Trial 8,342$ Bayer Inc. IVIG-C %10 Rapid Infusion Trial in Primary Immune Deficient PatientsCardiology Bernstein Clinical Trial 6,560$ MRC: Clinical Trials Heart Outcomes Prevention Trial (HOPE)

Cardiology Bernstein Clinical Trial 35,012$ Eli Lilly Canada Inc. Ruth Study, Raloxifene Hydrochloride or placebo in postmenopausal women at risk for major cardiovascular events.

Cardiology Bernstein Clinical Trial 36,426$ Pfizer Canada Inc. IMAGINE - Ischemia Managment with Accupril post bypass graft via inhibition of converting enzyme (IMAGINE): An on evaluation of the effect of 12 to approzimately 24 months treatmetn with Quinapril 40 mg QD post CABG surgery Ismetic events.

Cardiology Bernstein Clinical Trial 11,784$ Pfizer Canada Inc. A2581087 (ACTFAST): Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Multicentre 12 Wk Treatment Single Step Titration Open-Label Study Assessing the % of Dyslipidemic High-Risk Patients Achieving Low Density Lipo...

Cardiology Bernstein Clinical Trial 9,150$ National Institutes of Health STICH: Surgical Treatment for Ischemic Heart Failure

Cardiology Bernstein Clinical Trial 23,770$ Knoll Pharmaceuticals PEACE - Prevention of Events with Angiotensin Converting Enzyme Inhibition

Cardiology Bernstein Clinical Trial 3,513$ Astra Pharmaceuticals CANDESARTAN CILEXETIL (Candesartan) heart failure assessment of reduction in mortality and morbidity (CHARM) 3 protocols AHS-0003 0006 0007

Cardiology Bernstein Clinical Trial 10,564$ Novartis Pharmaceuticals Canada Inc Multinational multi centre double blind, randomized active controlled parallel group study comparing the efficacy and safety of long term treatment with valsartan, captopril and their combination on mortality in high risk patients after mt

Cardiology Bernstein Clinical Trial 802$ Bristol-Myers Squibb Company (Cda) Protocol CV137-068 (OVERTURE): Omapatrilat versus enalapril randomized trial of utility in reducing events

Cardiology Bernstein Clinical Trial 2,000$ CIHR: Health Research Institutes Atrial Fibrillation and congestive Heart Failure

Cardiology Bernstein Clinical Trial 999$ Myogen Inc. ESSENTIAL: MY-021-The Study of Oral Enoximone Therapy in Advanced Heart Failure: A Phase III Randomized Double-Blind Multicentre Parallel Group Placebo-Controlled Study of Oral Enoximone vs Placebo in Advanced Chronic Heart Failure Subjects

Cardiology Bernstein Clinical Trial 18,327$ Hamilton Health Sciences Corporation ONTARGET: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

Cardiology Bernstein Clinical Trial 16,336$ Vasogen Inc. Protocol 0202 (ACCLAIM): Multicenter Randomized Double-Blind Parallel Group Placebo-Controlled Study to Assess the Effects of Immune Modualtion Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure

Cardiology Bernstein Clinical Trial 12,924$ Vasogen Inc. Protocol 0101: Multicenter Randomized Double-Blind Parallel Group Placebo Controlled Study of Efficacy & Safety of Immune Modulation Therapy in Improving Walking Distance in Patients with Intermittent Claudication Secondary to PAD

Cardiology Bernstein Grant 37,536$ Various pharmaceutical companies Cardiology Research

Cardiology Bernstein Grant 10,000$ VHHSC: Interdisciplinary Grant Magnesium use in the prevention of atrial arrhythmias after cardiac surgery

Cardiology Buller Clinical Trial 2,133$ National Heart, Lung and Blood Institute OAT: Occluded Artery Trial - Total Occlusion Study of Canada 2 (TOSCA 2) Substudy

Cardiology Buller Clinical Trial 14,288$ Gen Vec A Phase 2 randomized, multicenter, 26 week study to assess the efficacy and safety of CI-1023 delivered through minimally invasive surgery versus maximum medical treatment in patients with severe angina, advanced coronary artery disease anf

Cardiology Buller Clinical Trial 17,850$ Organon Canada Ltd. Protocol ASPIRE Pilot: Randomized Blinded Pilot Trial of Fondaparinux Sodium (Arixtra) vs Unfractioned Heparin in Addition to Standard Therapy in a Broad Range of Patients Undergoing Percutaneous Coronary Intervention

Cardiology Buller Clinical Trial 14,914$ The Medicines Company REPLACE-2: Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, part 2-Protocol:TMC-BIV-01-03

Cardiology Buller Clinical Trial 25,650$ Canadian Vigour Centre Protocol CVC1002: The WEST Study: Which Early ST Elevation Myocardial Infarction Therapy

UBC Department of Medicine 83 Annual Report 2003




Cardiology Buller Clinical Trial 6,243$ Arginox Pharmaceuticals, Inc. ARG-101-061503 SHOCK 2: Randomized Double-Blind Placebo-Controlled Dose-Ranging Study of Nitric Oxide Synthase Inhibition with Ng Monomethyl-L-Arginine (L-NMMA) in Pts with Cardiogenic Shock Complicating Acute Myocardial Infarction: Preli..

Cardiology Buller Clinical Trial 4,000$ eVasc Medical Devices Inc. ROSSE: The eVasc Renal Ostial Stent System Evaluation

Cardiology Buller Clinical Trial 5,864$ NIH (US): Research Grant Total Occlusion Study of Canada-2 (TOSCA-2) An Angiographic Substudy of the Occluded Artery Trial (OAT)

Cardiology Buller Clinical Trial 6,457$ Abbott Laboratories DISTINCT PAS (Post-approval study)

Cardiology Buller Contract 5,553$ Guidant Corporation In Vivo Evaluation of the WTO guide wire, a Non-Glp StudyCardiology Buller Grant 30,000$ VHHSC Clinical Investigator Award: Christopher

BullerTesting the Late Open Artery Hypothesis.

Cardiology Carere Agreement 10,170$ MRC: Clinical Trials Clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) Trial

Cardiology Carere Clinical Trial 24,647$ Johnson & Johnson Arterial revascularization therapies study (ARTS)

Cardiology Carere Grant 52,756$ St Lukes-Roosevelt Institute For Health Sciences Open Artery Trial (OAT II)

Cardiology Chan, S Grant 60,216$ H&SFBC: Research Lipid lowering effects on LDL subclasses and endothelial functionCardiology Fung Clinical Trial 4,420$ Canadian Heart Research Centre Protocol CHRC 248: Canadian Registry of Acute Coronary Syndrome Patients: ACS Registry 2

Cardiology Fung Clinical Trial 7,086$ Baylor College of Medicine A randomized prospective multicentre trial evaluating the role of adenosine Tc-99M sestamibi single-photon emission computed tomography for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction

Cardiology Fung Clinical Trial 2,535$ Velocimed, Inc. Protocol 0231-001 (The Proximal Trial) Proximal Protection During Saphenous Vein Graft Intervention Using the Proxis Embolic Protection System: A Randomized Prospective Multicentre Clinical Trial

Cardiology Gin Clinical Trial 1,500$ Canadian Vigour Centre PREMIER Study: Multicentre Randomized Double-Blind Parallel-Group Placebo-Controlled Study of a 200 mg Oral Dose of PG-116800 Given Twice Daily for 90 Days to Patients Following Acute Myocardial Infarction with Post-Treatment Follow-up

Cardiology Gin Clinical Trial 19,005$ Pharmacia (Canada) Inc. IE3 99-02-035, Double blind, randomized, placebo controlled trial evaluating the safety and efficacy of Eplerenone in patients with heart failure following acute Myocardial Infarction.

Cardiology Gin Clinical Trial 5,823$ AstraZeneca Canada Inc Protocol DISCOVERY: Direct Statin Comparison of LDL-C Values: An Evaluation of Rosuvastatin Therapy

Cardiology Hamburger Clinical Trial 9,600$ Berlex Canada Inc. Protocol 305602 (AGENT-4): A Multinational Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Saftey of Ad5FGF-4 in Patients with Stable Angina

Cardiology Hamburger Clinical Trial 12,281$ Boston Scientific Corporation FILTERWIRE(TM) during transluminal intervention of saphenous vein grafts (SVG)

Cardiology Hamburger Clinical Trial 56,287$ Atherogenics, Inc. Safety and efficacy of AGI-1067 as an agent to prevent post angioplasty restenosis and coronary atherosclerosis progression (CART II)

Cardiology Hamburger Clinical Trial 10,762$ Boston Scientific Corporation Filterwire During Transluminal Intervention of Saphenous Vein Grafts

Cardiology Humphries Grant 80,000$ MSFHR: Career Investigator Program C1-SCH-67(01-2) (Humphries, Karin)

Secondary prevention - the gap between evidence and practice

Cardiology Humphries Grant 24,990$ MSFHR: Career Investigator Program C1-SCH-67(01-2)

Establishment Grant: Secondary prevention - the gap between evidence and practice

Cardiology Humphries Grant 25,000$ MSFHR: Career Investigator Program C1-SCH-67(01-2)

Matching Establishment Grant: Secondary prevention - the gap between evidence and practice

Cardiology Humphries Grant 56,938$ CIHR: Operating Grant MOP 57884 Secondary prevention - the gap between evidence and practiceCardiology Ignaszewski Clinical Trial 34,238$ Parke-Davis Pharmaceuticals The effect of LDL-cholesterol lowering beyond currently recommended minimum targets on

coronary heart disease (CHD) recurrence in patients with per-existing CHD

UBC Department of Medicine Page 184 Annual Report 2003




Cardiology Ignaszewski Clinical Trial 15,188$ Amgen, Inc. A double-blind, randomized, placebo-controlled, multicentre study to assess the impact of subcutaneous (SC) Darbepoetin Alfa treatment on exercise tolerance in subjects with symptomatic congestive heart failure (CHF) and anemia

Cardiology Ignaszewski Clinical Trial 5,847$ Myogen Inc. ESSENTIAL: A Phase III, randomized, double-blind, multicenter, parallel group, placebo-controlled study of oral Enoxiomone vs placebo in advanced chronic heart failure subjects

Cardiology Jue Clinical Trial 43,430$ Aventis Pharmaceuticals Inc. The Synergy Trial: A Prospective, Randomized, Open-Label, Multicentre Study in Patients Presenting with Acute Coronary Syndromes (ACS).

Cardiology Jue Clinical Trial 2,300$ Guidant Corporation CAFÉ: Canadian Atrial Fibrillation Evaluation Study

Cardiology Jue Clinical Trial 2,000$ Servier Canada Protocol IC3-9490-001-CAN: PRIME-DHF - Perindopril & Management of Diastolic Heart Failure: ACE Inhibitor Therapy in Diastolic Heart Failure; A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Cardiology Jue Clinical Trial 4,641$ Pfizer Canada Inc. A2581087 (ACTFAST): Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Multicentre 12 Wk Treatment Single Step Titration Open-Label Study Assessing the % of Dyslipidemic High-Risk Patients Achieving Low Density Lipo...

Cardiology Jue Contract 18,375$ Various Sources Echo Research Account

Cardiology Kerr Clinical Trial 3,920$ Various US Companies SHOCK - Should we emergently revascularize occluded coronaries for cardiogenis shock: an international randomized trial of emergently PTCA/CABG

Cardiology Kerr Clinical Trial 32,863$ Procter & Gamble, Canada A multi-centre, six-month, double-blind, placebo-controlled, parallel-group design clinical study to assess the efficacy and safety of a daily oral dose of 125mg of Azimilide Dihydrochloride for the prophylactic treatment of atrial fibrilli

Cardiology Kerr Clinical Trial 6,131$ Procter & Gamble, Canada A six month multi-center, double-blind, placebo-controlled, parallel-group design clinical study to assess the efficacy and safety of a 125mg daily oral dose of Azimilide Dihydrochloride for the treatment of atrial fibrillation in patients

Cardiology Kerr Grant 130,060$ Procter & Gamble, Canada The Canadian Registry of Atrial Fibrillation IIb - A prospective study of the natural history of new onset atrial fibrillation

Cardiology Mancini Contract 10,000$ Canadian Vigour Centre, University of Alberta The WEST Study: Which Early ST Evaluation Myocardial Infarction Therapy?

Cardiology Mancini Grant 246,672$ Various Sources Carotid studies

Cardiology Mancini Grant 10,000$ VHHSC: Scholar Award Preventing work loss from inflamatory arthritis: program development and pilot testing

Cardiology Rabkin Clinical Trial 1,240$ Hoechst-Roussel Pharmaceuticals, US Clinical Trials

Cardiology Rabkin Contract 1,240$ Various Pharmaceutical Companies Clinical TrialsCardiology Rabkin Grant 41,665$ VHHSC: VGH/UBC Fdn Special Opportunities

Research FundPharmacogenetics in the Management of Hypertension

Cardiology Ricci Clinical Trial 60,931$ Eli Lilly Canada Inc. Protocol H7T-MC-TAAH (JUMBO-TIMI 26): Double-Blind Randomized Multicenter Dose-Ranging Trial of CS-747 Compared with Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention - Joint Utilization of Medications to Block Plate...

Cardiology Straatman Clinical Trial 10,384$ Novartis Pharmaceuticals Canada Inc A 12-month, multicentre, randomized, adaptive design, open-label study to evaluate the benefit of C-2 hour monitoring of Neoral(R) on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basilixmab induction

Cardiology Thompson Clinical Trial 2,947$ Thoratec Laboratories Corporation Clinical study of the Thoratec Aria coronary artery bypass grafta one-sided equivalency study to demonstrate that the Thoratec ARIA is substantially equivalent or better than marginal quality autologous vessel graft (the control group)

Cardiology Tung Clinical Trial 2,000$ Medtronic (USA) SAVE PACe - Search AV Extension for Promoting Atrioventricular Conduction

Cardiology Webb Clinical Trial 33,338$ Eli Lilly and Company, US A Double-Blind, Randomized, Multicentre, Dose-Ranging Trial, of CS-747 compared with Clopidogrel in subjects Undergoing Percutaneous Coronary Intervention; Joint Utilization of Medications to Block Platelets Optimally (JUMBO-TIMI 26 study)





Cardiology Webb Clinical Trial 9,600$ Berlex Canada Inc. A European and Canadian Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina (AGENT-4)

Cardiology Webb Clinical Trial 819$ The Medicines Company A randomized evaluation of PCI linking Angiomax to reduced clinical events, part 2 (REPLACE-2)

Cardiology Webb Clinical Trial 3,062$ Arginox Pharmaceuticals, Inc. SHOCK-2 Trial-A ramdomised,double-blind,placebo-controlled,dose-ranging study of Nitrous Oxide Synthase inhibition with Ng-Monomethyl_L-Arginine (L-NMMA) in patients with cardiogenic shock complicating acute myocardial infarction: prelimina

Cardiology Webb Clinical Trial 20,195$ VELOCIMED, INC Proximal Protection during Saphenous Vein Graft Intervention using the Proxis TM Embolic Protection System: A Randomized,Prospective, Multicenter, Clinical Trial (PROXIMAL)

Cardiology Webb Clinical Trial 3,000$ Kerberos Proximal Solutions, Inc Canadian EMI Registry

Cardiology Webb Clinical Trial 215,690$ PercuSurge Inc. Enhanced myocardial efficacy and recovery by aspiration of liberalized debris (EMERALD) P02-0040

Cardiology Webb Clinical Trial 42,721$ Boston Scientific Corporation SYMBIOT III: A prospective randomized trial evaluating the Symbiot III covered stent system in saphenous vein grafts

Cardiology Webb Grant 1,500$ Heart & Stroke Foundation of Ontario The STREAM Study: Stent Restonosis and Metabolism

Cardiology Webb Grant 60,000$ Tyco Healthcare Group Canada Inc. Acetylcysteine in the prevention of reduced renal function after heart catheterization

Cardiology Webb Grant 16,000$ Various SourcesCardiology Yeung, John Clinical Trial 39,290$ Medtronic (USA) Medtronic EMPIRIC Study - Evaluation of EMPIRIC Programming to Improve Patient

ManagementCritical Care Chittock Clinical Trial 7,800$ CIHR: Randomized Controlled Trials (Clinical Trials) VASST: Randomized Controlled Trial of Vasopressin vs. Norepinephrine in Septic Shock

Critical Care Chittock Clinical Trial 40,178$ Society of Critical Care Medicine VICS: Effect of Measuring Sedation and Agitation on Duration of Mechanical Ventilation

Critical Care Chittock Grant 34,345$ VHHSC: VGH/UBC Fdn Special Opportunities Research Fund

The Vancouver Interaction and Calmness Scale in Mechanically Ventilated Patients: A Prospective Randomized Controlled Trial of the Effect of Measuring Sedation and Agitation on the Duration of Mechanical Ventilation

Critical Care Dodek Grant 4,000$ HC/CIHR: Research Project Improving the quality and end of life care in Canada: Understanding the perspectives of seriously ill patients and their caregivers

Critical Care Dodek Grant 19,700$ BC Medical Services Foundation Determinants of outcomes for critically ill patients who are transported between hospitals

Critical Care Dodek Grant 37,851$ CIHR: Operating Grant Geographic variation in outcomes of critical care in BC: The role of ICU organizational factors

Critical Care Dorscheid Grant 63,873$ Parker B Francis Fellowship in Pulmonary Research Corticosteroid-induced airway epithelial cell apoptosis

Critical Care Dorscheid Agreement 51,666$ NIH (US): Research Grant Eosinophil-Airway Epithelial Fas-FasL Interactions

Critical Care Dorscheid Grant 22,000$

MSFHR: Matching Establishment Grant CI-SCH-31(01-2)

Matching establishment grant: airway epithelial injury as a result of corticosteroid-induced apoptosis

Critical Care Dorscheid Grant 27,000$ BC Lung: Project Grant Airway epithelial damage, viral infection and excessive apoptosisCritical Care

Dorscheid Grant 37,500$ MSFHR: Career Investigator Program C1-SCH-31 (01-2) Establishment grant: Airway epithelial injury as a result of corticosteroid-induced apoptosis

Critical Care Dorscheid Grant 48,000$

NIH (US): Research Grant In Collaboration with: University of Chicago Eosinophil-Airway Epithelial Fas-Fasl Interactions

Critical Care Dorscheid Grant 78,314$ H&SFBC: Research Endothelial FasL Expression and Reperfusion InjuryCritical Care

Dorscheid Grant 80,000$ MSFHR: Career Investigator Program C1-SCH-31(01-2) (Fellow: Dorscheid, Delbert) Airway epithelial injury as a result of corticosteroid-induced apoptosis

Critical Care Dorscheid Grant 80,069$ CIHR: Operating Grant # MOP-43898 Airway epithelial injury as a result of corticosteroid-induced apotosis





Critical Care Fenwick Clinical Trial 2,656$ Eli Lilly Canada Inc. An open-label study of recombinant human activated protein C (LY203638) in patients with severe sepsis (F1K-MC-EVBF)

Critical Care Fenwick Clinical Trial 2,758$ Suntory Ltd. Protocol SPI-001(Canada): Phase II Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Dose-Ranging Evaluation of the Safety & Efficacy of a-hANP Infusion (Carperitide for Injection; Sun 4936) in Patients with Acute.(ARDS)

Critical Care Fenwick Clinical Trial 9,084$ Eli Lilly Canada Inc. Protocol F1K-MC-EVBR: Randomized Double-Blind Placebo-Controlled Trial of Prophylactic Heparin in Patients with Severe Sepsis & Higher Disease Severity Who Are Undergoing Treatment with Drotrecogin Alfa (Activated)

Critical Care Fenwick Clinical Trial 11,578$ ICOS Corporation A Phae 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet Activating Factor Acetylhydrolase (rPAF-AH) for Reducing 28 Day All Cause Mortality in Patients with Severe Sepsis.

Critical Care Fenwick Clinical Trial 15,371$ Eisai Inc. Protocol E5564-A001-201: Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Intravenous Infusions in Patients with Severe Sepsis

Critical Care Fenwick Clinical Trial 20,400$ Leo Pharmaceutical Research Fdn Protocol HL 0101 INT: HL 10 Three Dosages in ALI/ARDS

Critical Care Fenwick Clinical Trial 56,144$ Eli Lilly Canada Inc. Protocol F1K-MC-EVCL: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Early Stage Severe Sepsis

Critical Care Ronco/Henderson Grant 10,000$ VHHSC: Mentored Clinical Scientist Operating: Survival Using Glucose Algorithm Regulation (Sugar) Trial

Critical Care Ronco/Henderson Grant 50,000$ VHHSC: Mentored Clinical Scientist Salary: Survival using glucose algorithm regulation (SUGAR) trial

Critical Care Ronco Clinical Trial 8,850$ MRC: Clinical Trials LOVS: A randomized trial of a Lung Open Ventilation Strategy in Acute Lung Injury (MRC #78042)

Critical Care Ronco Grant 10,000$ VHHSC: VGH/UBC Fdn Special Opportunities Research Fund

Survival Using Glucose Algorithm Regulation (SUGAR) Trial

Critical Care Ronco Grant 25,000$ Canadian Critical Care Foundation Survival Using Glucose Algorithm Regulation (SUGAR) Trial

Critical Care Ronco Grant 46,200$ Cdn Diabetes Assoc: Charles H. Best Fund/Grant-in-Aid

Survival Using Glucose Algorithm Regulation (SUGAR) Trial

Critical Care Russell Clinical Trial 23,150$ Eli Lilly and Company, US An open-label study of recombinant human activated protein C in severe sepsis: A phase 3b clinical trial (Protocol F1K-MC-EVBF)

Critical Care Russell Clinical Trial 34,864$ Eli Lilly and Company, US Efficacy and safety of Drotrecogin Alfa (activated) in adult patients with early stage severe sepsis

Critical Care Russell Contract 6,325$ MRC: Clinical Trials A randomized trial of a lung open ventilation strategy in acute lung injury

Critical Care Russell Grant 22,500$ BC Lung: Project Grant Genetics of acute respiratory distress syndrome (ARDS)Critical Care Russell Grant 15,000$ UBC and Providence Health Care Genetics of ARDSCritical Care Russell Grant 532,454$ CIHR: Clinical Trials MCT-44152 Randomized controlled trial of vasopressin vs. norepinephrine in septic shockCritical Care Tsang Grant 30,000$ BC Lung: Project Grant Endothelins and the mechanism of hypoxemia in acute pulmonary embolismCritical Care

Walley Grant 37,500$ MSFHR:Establishment Grant C1-DSH-73(02-1)Translating mechanistic understanding of the systemic inflammatory response syndrome (SIRS) to clinical practice via genomics

Critical Care Walley Grant 76,891$ H&SFBC: Research Mechanism of Myocardial Dysfunction during SepsisCritical Care

Walley Grant 80,952$ CIHR: Operating Grant MOP 57774Influence of polymorphisms in coagulation pathway in inflammatory mediator genes on phenotype post-cardiopulmonary bypass surgery

Critical Care Walley Grant 90,000$

MSFHR: Distinguished Scholar Award CI-DSH-73(02-1) Fellow: Walley, Keith

Translating mechanistic understanding of the systemic inflammatory response syndrome (SIRS) to clinical practice via genomics

Critical Care Walley Grant 109,661$ CIHR: Operating Grant MOP-53051 Myocardial Dysfunction Induced by ICAM-1 binding.

Dermatology Dutz Grant 12,611$ MRC Operating Grant MOP37952 Epicutaneous priming of T lymphocytes function

Dermatology Dutz Grant20,000$

VPR Research Development Fund Treating type I diabetes melitus by modulating cross-presentation

Dermatology Dutz Grant24,982$

CIHR/Strategic: Request for Applications RFA: New Discoveries - High Risk Grant: Tolerance induction by skin immunization





Dermatology Dutz Grant 29,850$ MSFHR: SARS Accelerated Vaccine Initiative PJ- SAV-004

Identification of class 1-restricted SARS epitopes

Dermatology Dutz Grant35,000$ UBC Department of Medicine Epicutaneous modulation of T lymphocyte function for the optimization of immunization

Dermatology Dutz Grant35,000$ Cdn Dermatology Fdn: Research Grant Epicutaneous immune response modification for vaccine optimization

Dermatology Dutz Grant 45,000$ Arthritis Society/CIHR: New Investigatorship Award # 401, (Dutz, Jan)

Transcutaneous T cell priming

Dermatology Dutz Grant 50,000$ Arthritis Society: Research TAS01/0116 UV Light, Apoptosis and T Cell Priming in the SkinDermatology Dutz Grant 79,100$ BCRICWH: Investigatorship Award BCRICWH Investigatorship award - Dr. Jan Dutz

Dermatology Dutz Grant 60,000$ Canadian Institute of Health Research (CIHR) Tolerance induction by skin immunizationDermatology Dutz Grant 68,799$ Canadian Diabetes Association Autoreactive CTL in DiabetesDermatology Ho Grant 44,582$ Canadian Institute of Health Research (CIHR) The role of p33ING1 of UV-damaged DNA

Dermatology Ho Clinical Trial 54,800$ Novartis Pharmaceuticals Canada Inc CASM981CJP01(ASM981C): Open-Label Multicenter Study to Assess Blood Concentrations Tolerability & Efficacy of ASM981 in Japanese Infants & Children with Atopic Dermatitis Treated Topically for 3 Weeks with 1% ASM981 Final Market Formulation

Dermatology Ho Clinical Trial 2,560$ Novartis Pharmaceuticals Canada Inc RAINBOW: A Multicenter, Single Arm Prospective, Open Label Study to Assess the Safety of Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic Dermatitis

Dermatology Ho Clinical Trial 16,800$ Fujisawa Canada Inc. FG-506-06-33: Long-Term Non-Comarative Study to Evaluate the Safety and Efficacy of Tacrolimus Ointment in Paediatric Patients

Dermatology Ho Clinical Trial 33,000$ Novartis Pharmaceuticals Canada Inc CASM981C2315: 26-week Randomized Multicenter Parallel-Group Double-Blind Vehicle-Controlled Study to Evaluate the Incidence of Atopic Dermatitis Flares When ASM981 (pimecrolimus) Cream 1% is Used at the First Signs and/or Symptoms of Ato..

Dermatology Ho Clinical Trial 75,352$ Abbott Laboratories Protocol M02-529: Phase II Multicenter Extension Study of the Safety & Efficacy of Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Dermatology Ho Clinical Trial 32,000$ Fujisawa Canada Inc. FG-506-06-32: Randomized Multicentre Double-Blind Pharmacokinetic Study of Tacrolimus Ointment (0.03%) in Paediatric Patients (aged 3 months to 24 months) with Atopic Dermatitis Following First and Repeated Once Daily or Twice Daily .....

Dermatology Ho Clinical Trial 30,000$ Genmab A/S Protocol Hx-CD4-006: A Double-Blind Placebo Controlled Randomized Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients with Moderate to Severe Chronic Plaque Psoriasis Vulgaris

Dermatology Ho Clinical Trial 124,617$ Boehringer Ingelheim (Canada) Ltd. 1175.19: Phase IIb Placebo-Controlled Parallel Randomized Double-Blind 26 Wk Efficacy & Safety Trial of BIRB 796 BS Tablets of 30, 50 and 70mg bid in Pts with Moderate to Severe Psoriasis who are Candidates for Systemic Treatment of Phot...

Dermatology Ho Clinical Trial 64,500$ Biogen, Inc. C-738: Randomized Dose-Blinded Multicenter Study Comparing the Efficacy & Safety of Weekly Intravenous Administration of 7.5 mg of Alefacept (LFA-3/IgG1 Fusion Protein) Over 12 Wks with an Extension to 16 Weeks & 0.075 mg/kg over 12 Wks ...

Dermatology Ho Clinical Trial 64,376$ Abbott Laboratories, Limited (Canada) Protocol M02-528: Phase 2 Multicentre Study of the Safety and Efficacy of Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Dermatology Ho Grant 10,000$ Cdn Dermatology Fdn: Research Grant The role of p33ing in the UV-induced apoptosis of melanoma cellsDermatology Ho Grant 15,000$ Donation Skin Cancer Research and Miscellaneous SupportDermatology Hong Grant 3,000$ Dean of Medicine: Strategic Teaching Initiative Internet based self-directed learning and evaluation of medical studentsDermatology Kitson Clinical Trial 2,560$ Novartis Pharmaceuticals Canada Inc RAINBOW: A Multicenter, Single Arm Prospective, Open Label Study to Assess the Safety of

Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic Dermatitis





Dermatology Li Grant 1,500$ NCIC/CCS: Student Travel Award 014619 (Fellow: Campos, Eric)

Characterization of mutations in the ING1 tumor suppressor gene in human melanoma

Dermatology Li Grant 2,500$ MSFHR: Doctoral Trainee Research Award STPHD63020 (Fellow: Eric Campos)

Functional role of p33ING1 phosphorylation in cellular stress response to DNA damage

Dermatology Li Grant 12,500$ CIHR: Operating Grant DOP 62280 Mechanisms of the novel tumour suppressor p331NG1 in UV-induced apoptosis of melanoma cells

Dermatology Li Grant 20,000$ Cdn Dermatology Fdn: Research Grant The role of p33ING1 phosphorylation in celluar stress response to UV irradiationDermatology Li Grant 22,291$ CIHR: Operating Grant MOP-42465 Role of p33ING1 in repair of UV-damaged DNADermatology Li Grant 65,000$ Cdn Dermatology Fdn: Research Grant Role of P33ing1 in UV induced apoptosis

Dermatology Li Grant 87,210$ NCIC/CCS: Research Scientist 012443 Role of p33ing1 in repair of uv-damaged dnaDermatology Li Grant 126,846$ NCIC: Research Grant 01424 Functional role of p33ING1 phosphorylation in cellular stress response to DNA damageDermatology

Li Grant 133,660$ NCIC: Research Grant 014029 Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA and Apaf-1

Li Grant 120,000$ Cancer Research Society Role of PUMA and Apaf-1 in melanoma chemosensitivity

Dermatology Li Grant 19,530$ James A Winton Endowment Fund Mechanisms of curcumin-induced apoptosis in human melanoma cells

Dermatology Li Grant 20,000$ UBC CIHR Interim Fund Skin Cancer prevention by stabilization of p53

Dermatology Li Grant 25,000$ Canadian Dermatology Foundation Skin cancer prevention by pharmacological stabilization of p53 conformationDermatology Li Grant 6,000$ Canadian Melanoma Foundation

molecular patheways of p33ING1 enhancement of UV-induced apoptosis of melanoma cells

Dermatology Li Grant 35,000$ Canadian Dermatology Foundation Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA and Apaf-1Dermatology Lui Clinical Trial 2,560$ Novartis Pharmaceuticals Canada Inc Rainbow Study: A Multicentre, Single Arm Prospective, Open Label Study to Assess the Safety of

Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic dermatitis.

Dermatology Lui Clinical Trial 39,000$ QLT PhotoTherapeutics Inc. Protocol VFI MBCC 02: A Randomized, Placebo-Controlled, Masked, Multicentre, Phase III Study of Photodynamic Therapy with Verteporfin for Injection (VFI) for the Treatment of Multiple Basal Cell Carcinoma

Dermatology Lui Clinical Trial 75,792$ Biogen, Inc. Protocol C-733: An Open-Label Multicentre Study to Evaluate the Safety & Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients with Chronic Plaque Psoriasis

Dermatology Lui Clinical Trial 64,025$ Galderma Canada Protocol RD.06.SPR18091: An Open Label Safety and Efficacy Study of Solage (2% 4-Hydroxyanisole/0.02% Tretinoin) to Assess Pigmentary Changes in Ethnic Groups of Asian, Latin/Hispanic and African American Descent with Skin types II-V

Dermatology Lui Clinical Trial 43,128$ Leo Laboratories Canada Ltd Protocol KHO 0101: KH 1650 in Psoriasis Vulgaris Proof of Concept and Dose-Finding Study

Dermatology Lui Contract 8,694$ QLT Phototherapeutic CRA: Evaluation of the Q-switched Alexandrite laser for tattoo removal in guinea pigs (A comparison of the effects of Q-switched alexandrite laser and PDT with intradermal QL T0074 on tattoo removal in guinea pigs

Dermatology Lui Grant 15,000$ Canadian Dermatology Foundation Monitoring photoproduct formation as a real time dosimeter for photodynamiv therapyDermatology Lui Grant 30,000$ Canadian Dermatology Foundation Near-infrared fluorescence spectroscopy and imaging for skin cancer detection and evaluation

Dermatology Lui Grant 54,000$ Canadian Institute of Health Research (CIHR) Visible to near infrared fluorescence Excitation-Emission Matrix (EEM) spectroscopy system for skin characterization and diagnosis

Dermatology Lui Grant 45,000$ National Cancer Institute of Canada (NCIC) Rapid Raman spectroscopy for noninvasive diagnosis: application in skin cancer detection

Dermatology Lui Grant 4,780$ Canadian Institute of Health Research (CIHR) CIHR Skin Research Training Centre





Dermatology Rivers Clinical Trial 2,560$ Novartis Pharmaceuticals Canada IncRAINBOW: A Multicenter, Single Arm Prospective, Open Label Study to Assess the Safety of Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic Dermatitis

Dermatology Rivers Investigator Initiated Clinical Trial

35,000$ 3M Pulse Imiquimod for actinic keratoses

Dermatology Shapiro Clinical Trial 2,560$ Novartis Pharmaceuticals Canada Inc RAINBOW: A Multicenter, Single Arm Prospective, Open Label Study to Assess the Safety of Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic Dermatitis

Dermatology Shapiro Clinical Trial 200,000$ QLT PhotoTherapeutics Inc. Protocol T0074 AGA 002: Phase II Treatment Optimization Study of Photodynamic Therapy for Androgenetic Alopecia with Topical QLT0074

Dermatology Shapiro Clinical Trial 37,440$ Stiefel Labs International Division Protocol SCI-2002-01: A Study to Assess the Clinical Safety and Efficacy of a Ciclopirox Olamine Shampoo (Stieprox) Compared to a Placebo Shampoo in the Treatment of Seborrhoeic Dermatitis

Dermatology Shapiro Investigator Initiated Clinical Trial

39,348$ Natl Alopecia Areata Fdn: Research Grant Safety and Therapeutic Efficacy of Alefacept in Patients with Chronic Severe Alopecia Areata of the Scalp

Dermatology Shapiro Grant 20,000$ Cdn Dermatology Fdn: Research Grant Signal transduction pathways responsible for restoring hair growth in Alopecia AreataDermatology Shapiro Grant 36,000$ Nat'l Alopecia Areata Fdn: Research Grant Safety and Therapeutic Efficacy of Alefacept in Patients with Chronic Severe Alopecia Areata of

the Scalp

Dermatology Shapiro Grant 50,000$ Galderma Canada Melanogenesis regulation in graying human hair follicles

Dermatology Shapiro Grant 10,000$ Canadian Dermatology Foundation Pro-inflammatory cytokines in the pathogenesis of alopecia areata

Dermatology Shapiro Grant 60,000$ Canadian Hair Research Foundation Alopecia areata model of autoimmunityDermatology Zhou Clinical Trial 2,560$ Novartis Pharmaceuticals Canada Inc

RAINBOW: A Multicenter, Single Arm Prospective, Open Label Study to Assess the Safety of Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic Dermatitis

Dermatology Zhou Grant 30,000$ VHHSC Scholar Award (Zhou, Youwen) Molecular Pathogenesis of Sezary Syndrome - Gene Signatures of Sezary CellsDermatology Zhou Grant 35,000$ Cdn Dermatology Fdn: Research Grant T-plastin in Sezary Syndrome and Mycosis Fungoides: pathogenic significance and clinical

applications

Dermatology Zhou Grant 67,000$ Dermatology Foundation (USA) Gene expression profiling of Rosacea (National Rosacea Scoiety)

Dermatology Zhou Grant 366,100$ Canada Foundation for Innovation (CFI) Centre for predictive medicine and therapeutics

Dermatology Zhou Grant 35,000$ University of British Columbia T-plastin in Sezary syndrome and mycosis fungoides

Dermatology Zhou Grant 50,000$ Canadian Dermatology Foundation Molecular Pathogenesis of Sezary Syndrome

Dermatology Zhou Grant 25,000$ UBC Galderma Rsearch Fellowship Clinical-Experimental Dermatology

Dermatology Zhou Grant 35,000$ Canadian Dermatology Foundation Molecular disease markers

Dermatology Zhou Grant 200,000$ China National Sciences Foundation Gene expression signatures of rheumatoid arthritis

Endocrinology Dawson Clinical Trial 3,670$ Hoechst-Roussel Pharmaceuticals, US HOPE Study: Heart Outcomes Prevention Evaluation

Endocrinology Elliott Clinical Trial 22,079$ Boehringer Ingelheim (Canada) Ltd. 502.397 (AMADEO): Prospective Randomized Double-Blind Double-Dummy Forced-Titration Multicentre Parallel-Group 1 Yr Treatment Trial to Compare Micardis (telmisartan) 80mg vs Cozaar (Losartan) 100mg in Hypertensive Type 2 Diabetic Pts with..

Endocrinology Elliott Clinical Trial 55,981$ Novartis Pharmaceuticals Canada Inc NAVIGATOR: Multinational Randomized Double-Blind Placebo-Controlled Forced-Titration 2x2 Factorial Design Study of the Efficacy & Safety of Long Term Administration of Nateglinide & Valsartan in the Prevention of Diabetes & Cardiovascular..

Endocrinology Elliott Clinical Trial 137,633$ National Institutes of Health Action to control Cardiovascular Risks in Diabetes (ACCORD) Trial

Endocrinology Prior Grant 1,497$ Donations for Health Science Research Exercise, Reproduction and Health Research Fund

Endocrinology Prior Grant 4,700$ Various Sources Centre for Menstrual Cycle and Ovulation Research





EndocrinologyPrior Grant 22,604$ CIHR/Rx&D: Research Program (CAMOS) Canadian multicentre osteoporosis study - a cross sectional and prospective

observational study of bone density, bone strength and fracture risk

Endocrinology

Prior Grant 36,600$ Cancer Care Ontario in collaboration with: Canadian Institutes of Health Research

(CAMOS) Canadian multicentre osteoporosis study - a cross sectional and prospective observational study of bone density, bone strength and fracture risk.

Endocrinology Sadar Grant 500$ CIHR: Doctoral Research Awards JMO 58977 In collaboration with: Canadian Prostate Cancer Research Initiative (Fellow: Quayle, Steven)

Identification of new targets for the treatment of androgen-independent prostate cancer

Endocrinology Sadar Grant 2,500$ 1)BM (Fellow: Quayle, Steven) Identification of new targets for the treatment of androgen-independent prostate cancer

Endocrinology Sadar Grant 100,000$ Health Canada Androgen independence

Endocrinology Sadar Grant 102,000$ Health Canada Potential new therapy for androgen independent

Endocrinology Thompson Clinical Trial 5,000$ Novo-Nordisk A randomized, parallel-group, open-label, multinational trial comparing the safety and efficacy of insulin aspart (NovoRapid) versus human insulin (Actrapid) used in a multiple injection regimen, in the treatment of pregnant women with typ

Endocrinology Thompson Grant 50,154$ CIHR: Health Research Institutes To reduce IDDM in type 1 diabetes in the genetically at risk TRIGR

Gastroenterology Anderson Clinical Trial 342$ Bristol-Myers Squibb Company (Cda) Protocol AI463049: Long-term Assessment of Treatment Outcomes with Entecavir & Lamivudine for Chronic Hepatitis B Infection in Patients Who Have Enrolled in Phase III Entecavir Trials

Gastroenterology Anderson Clinical Trial 895$ Bristol-Myers Squibb Pharmaceutical Group (Cda) Protocol AI463-901: A Preliminary Assessment of Safety and Antiviral Activity of Open-Label Entecavir Plus Lamivudine Therapy in Subjects with Chronic Hepatitis B Who Have Viremia on Monotherapy in Other Entecavir Trials

Gastroenterology Anderson Clinical Trial 1,279$ Millennium Pharmaceuticals Inc. Phase II randomized, placebo controlled, double blind, parallel group, multicentre study to determine the safety, pharmacokinetics and effectiveness of LDP-02 in patients with mildly to moderately active Ulcerative colitis

Gastroenterology Anderson Clinical Trial 1,466$ Centocor Accent I: Randomized double blind, placebo-controlled trial of anti-TNfx chimeric monoclonal antibody (Infliximab, remicade) in the long term treatment of patients with moderately to severely active Crohn's Disease

Gastroenterology Anderson Clinical Trial 1,924$ Celltech Chiroscience Inc. (32 week).A Phase III, multi-national, multi-site, open label 32 week long term follow-up study to assess the safety and efficacy of the engineered human anti-TNFa antibody, CDP571, in patients with Crohn's Disease. (014)

Gastroenterology Anderson Clinical Trial 4,078$ Protein Design Labs, Inc. Protocol DAC-1008: Phase II Randomized Double-Blind Placebo-Controlled Multicenter Dose-Ranging Study of Intravenous Daclizumab in Patients with Moderate to Severe Ulcerative Colitis

Gastroenterology Anderson Clinical Trial 5,521$ Centocor C0168T26 Accent II: A randomized double blind, placebo controlled trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, remicade)in the long term treatment of patients with fistulizing Crohn's Disease (BBD-IND 5389)

Gastroenterology Anderson Clinical Trial 6,195$ Elan Pharmaceuticals Inc. Protocol ELN100226-CD351: Phase III Multicenter Open-Label Long-Term Study of the Safety Tolerability & Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects who have Previously Participated in Studies CD251 CD301 CD303

Gastroenterology Anderson Clinical Trial 6,280$ Schering Canada Inc. Protocol P02569: PEG-Intron as Maintenance Therapy vs an Untreated Control Group in Adult Subjects with Compensated Cirrhosis (METAVIR F4) Secondary to Chronic Hep C who have Failed to Respond to Therapy with Any alpha Interferon + Ribaviri

Gastroenterology Anderson Clinical Trial 7,665$ Elan Pharmaceuticals Inc. A Phase III International Multicentre Double-Blind Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Intravenous Antegren (natalizumab)(300 mg Monthly) in Maintaining Clinical Response and Remission in Subjects with Crohn

Gastroenterology Anderson Clinical Trial 8,017$ Tillotts Pharma AG Protocol TP0308: - EPIC-2 Phase III Randomized Placebo-Controlled Double-Blind Parallel Group Multicentre Study to Assess the Efficacy & Safety of Omega-3 Free fatty Acids (Epanova) for the Maintenance of Symptomatic Remission in Subjects..





Gastroenterology Anderson Clinical Trial 9,500$ Hoffmann-La Roche Ltd (Canada) BV16209E. Multicenter open label expended access program of Peginterferon alfa-2a (Ro25-8310) Monotherapy and Combination Therapy with Rivavirin (Ro 20-9963) in patients with Chronic Hepatitis C

Gastroenterology Anderson Clinical Trial 16,406$ Elan Pharmaceuticals Inc. A Phase III, International Multicentre, Double-Blind, Placebo Controlled Study of the Safety, Efficacy and Tolerability of Intravenous Antegren (Natalizumab) in Subjects with Moderately to Severely Active Crohn's Disease.

Gastroenterology Anderson Clinical Trial 19,003$ Protein Design Labs, Inc. ZAF-707: Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-y Monoclonal Antibody (HuZAF) Administered to Patients with Moderate to Severe Crohn's Disease

Gastroenterology Anderson Clinical Trial 22,280$ Bristol-Myers Squibb Company (Cda) AI463-022: Phase III study of the safety and antiviral activity of entecavir vs lamivudine in adults with chronic hepatitis B infection who are posititve for hepatitis B E antigen

Gastroenterology Anderson Clinical Trial 23,472$ Achillion Pharmaceuticals, Inc. Protocol ACH443-005: Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment with ACH 126,443 (B-L-Fd4C) in Adults with Lamivudine-Resistant Chronic Hepatitis B

Gastroenterology Anderson Clinical Trial 24,050$ Bristol-Myers Squibb Company (Cda) A1463-027 A Phase II Study of the safety and antiviral activity of entecavir vs lamivudine in adults with chronic hapatitis Binfection who are negative for hepatitis B E Antigen

Gastroenterology Anderson Clinical Trial 26,564$ Centocor Protocol C0168T37 (ACT 1): Randomized Placebo-Controlled Double-Blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative Colitis

Gastroenterology Anderson Clinical Trial 27,740$ Bristol-Myers Squibb Pharmaceutical Group (Cda) A Phase 3 Study of the Comparison of Entecavir to Lamivudine in Chronic Hepatitis B Subjects with Incomplete Response to Current Lamivudine Therapy

Gastroenterology Anderson Clinical Trial 63,183$ Schering Canada Inc. Protocol No. P02370: PEG-Intron Plus Rebetol for the Treatment of Subjects with Chronic Hepatitis C who Failed to Respond to Previous Combination Therapy (Any alpha Interferon Treatment in Combination with Ribavirin)

Gastroenterology Enns Clinical Trial 2,626$ GlaxoSmithKline An eight-week, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety of SB223412 in subjects with irritable bowel syndrome

Gastroenterology Enns Clinical Trial 5,659$ Abbott Laboratories A multi-center, randomised, double-blind, placebo-controlled study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of clinical remission in subjects with Crohn's disease. Clinical Study Protocol M02-0433

Gastroenterology Enns Clinical Trial 6,278$ GelTex Pharmaceuticals, Inc. A randomized, double-blind study of GT160-246 (GTC80-203) versus Vancomycin in patients with C. difficile associated diarrhea

Gastroenterology Enns Clinical Trial 6,305$ Byk Gulden Pharmaceuticals Initial study for the development and validation of a comprehensive questionnaire assessing disease-related symptoms in patients suffering from endoscopic negative gastroesophageal reflux disease and treated with Pantoprazole 20mg over 28 d

Gastroenterology Enns Clinical Trial 6,379$ Abbott Laboratories A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in subjects with Crohn's Disease

Gastroenterology Enns Clinical Trial 10,501$ Celltech Chiroscience Inc. A phase III, multi-national, multi-site, double-blind, placebo-controlled, 28-week study to assess the safety and efficacy of the engineered human anti-TNF alpha antibody, CDP571 (10mg/kg), in patients with active Crohn's disease

Gastroenterology Enns Clinical Trial 12,582$ Solvay Pharmaceuticals A randomized, double blind, placebo controlled, multinational study to investigate the safey and efficacy of 2mg TID of Cilansetron over 26 weeks in Diarrhea-Predominant Irritable Bowel Syndrome subjects (Protocol S2413009)

Gastroenterology Enns Clinical Trial 56,659$ NDO Surgical, Inc Study of the NDO endoscopic plication system for the treatment of symptomatic gastroesophageal reflux disease

Gastroenterology Enns Clinical Trial 72,005$ Abbott Laboratories A multi-center, randomised, double-blind, placebo-controlled study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of clinical remission in subjects with Crohn's disease. Clinical Study Protocol M02-403





Gastroenterology Enns Clinical Trial 118,125$ AstraZeneca Canada Inc A multicentre, randomized, double-blind study to compare the efficacy of healing and maintenance treatment with esomeprazole and pantoprazole in patients with reflux oesophagitis

Gastroenterology Enns Clinical Trial 171,080$ Negma-Lerads A phase II, multicentre, randomized, double-blind, parallel-group, dose response study to evaluate the efficacy and safety of tenatoprazole (10, 20 and 40mg daily) in patients with erosive or ulcerative esophagitis

Gastroenterology Enns Clinical Trial 474,839$ Elan Pharmaceuticals Inc. A phase III, international, multicenter, double-blind, placebo-controlled study of the safety, efficacy and tolerability of intravenous Antegren(TM) (natalizumab) in subjects with moderately to severely active Crohn's disease

Gastroenterology Enns Grant 4,120$ Altana Pharma, Inc. Symptom Relief in patients suffering from gastroesophageal reflux disease grade A to D according to Los Angeles classification treated with pantoprazole 40mg o.d or esomeprazole 40mg o.d over 4 weeks

Gastroenterology Enns Grant 10,000$ NSIR: Research Grant Colon Cancer Screening: What are we doing? Is it cost-saving?

Gastroenterology Enns Grant 10,000$ Canadian Society of Intestinal Research Colon cancer screening: What are we doing? Is it cost-saving?

Gastroenterology Gray Clinical Trial 16,708$ AstraZeneca Canada Inc Protocol SD-NED-0021 STARS I: Supportive Test for Acid-Related Symptoms with Esomeprazole & a Following 7 Week Double-Blind Randomized Placebo-Controlled Treatment Period in Subjects with Upper Gastrointestinal Symptoms & with Normal Find..

Gastroenterology Gray Clinical Trial 22,430$ AstraZeneca Canada Inc Protocol EXPO SH-NEG-0008: PPI Comparator Study to Compare the Efficacy of Healing & Maintenance Treatment with Esomeprazole & Pantoprazole in Subjects with Reflux Oesophagitis - A Multicentre, Randomized, Double-Blind Study

Gastroenterology Kwan Clinical Trial 18,700$ Idenix Pharmaceuticals, Inc. Protocol NV-02B-007: Randomized Double-Blind Trial of LdT (Telbivudine) vs Lamivudine in Adults with Compensated Chronic Hepatitis B

Gastroenterology Salh Grant 2,500$ MSFHR: Masters Trainee Research Award # 30(02-1)BM: Kuljit PARHAR

The Role of the Integrin Linked Kinase in Intestinal Inflammation

Gastroenterology Salh Grant 30,000$ NSIR: Research Grant The role of integrin - linked kinase in intestinal inflammation

Gastroenterology Salh Grant 75,000$ CCFC: Research Signalling and Inflammatory Bowel Disease: the Role od Stress-Activated Protein Kinases

Gastroenterology Steinbrecher Grant 500$ Donation Clinical Research in Chronic Liver Diseases

Gastroenterology Steinbrecher Grant 98,276$ CIHR: Operating Grant Pathogenesis of atherosclerosis

Gastroenterology Steinbrecher Grant 106,449$ H & SFBC: Research Regulation of Growth and Survival of macrophages by oxidized LDL.Gastroenterology Tai Grant 25,000$ Vancouver Coastal Health Authority - Operating

FundsLaboratory Start-up Fund

Gastroenterology Tai Grant 60,000$ NSIR: Research Grant Dissecting chemotherapy resistance in colorectal cancer using a genome-wide approach

Gastroenterology Tai Grant 75,000$ Dean of Medicine Laboratory Start-up Fund

Gastroenterology Tai Grant 100,000$ Various Sources Laboratory start-up fundGastroenterology Whittaker Clinical Trial 14,380$ Millennium Pharmaceuticals Inc. A phase II, randomized, placebo-controlled, double-blind, parallel group to determine the safety,

pharmacokinetics and effectiveness of LPD-02 in patients with mildly to moderately active Crohn's Disease

Gastroenterology Yoshida Clinical Trial 8,500$ Hoffmann-La Roche Ltd (Canada) BV16209 A Multicenter Open Label Expanded Access Program of Pegintereron alfa-2a (ro 25-8310) Monotherapy and Combination Therapy with Ribavirin (Ro20-9963) in Patients with Chronic Hepatitis C

General Internal Med. Hatala Grant 21,350$ RCPSC: Medical Education Research Grant Evaluation of a modified mini-clinical evaluation exercise as a high stakes assessment of clinical competence

General Internal Med. Khan Grant 7,500$ MSFHR:Postdoctoral Trainee Fellowship STPDF240021

The value of cardiac specific troponin in predicting cardiac outcomes in an asymptomatic chronic kidney disease population





General Internal Med. Khan Grant 43,083$ CIHR: Postdoctoral Fellowship MFE-63502 in collaboration with: Institute of Circulatory & Respiratory Health (CIHR)


General Internal Med. Magee Grant 8,750$ Sunnybrook Health Science Centre Control of hypertension in pregnancy - pilot study

General Internal Med. Magee Grant 25,000$ MSFHR: Matching Establishment Grant C1-SCH-57(02-1)

CHIPS (control of hypertension in pregnancy study): a pilot trial

General Internal Med. Magee Grant 37,500$ MSFHR: Matching Establishment Grant C1-SCH-57(02-1)

CHIPS (control of hypertension in pregnancy study): a pilot trial

General Internal Med. Magee Grant 60,000$ MSFHR: Scholar Award CHIPS (control of hypertension in pregnancy study): a pilot trialGeneral Internal Med. Palepu Grant 2,000$ CIHR: New Investigator Award (CIHR Scholarship) Social determinants and HIV: an evaluation of a community-based intervention in injection drug

users (research allowance)General Internal Med. Palepu Grant 39,626$ CIHR: Operating Grant HHP-63008 The role of injection drug use and hepatitis C infection on tolerability of highly active antiretroviral

therapy and HIV-1 treatment outcomesGeneral Internal Med. Palepu Grant 48,000$ CIHR: New Investigator Award (CIHR Scholarship)

# HNI-50103 (Fellow: Palepu, Anita)Social determinants and HIV: a community-based intervention in injection drug users

General Internal Med. Palepu/Hubley Grant 61,635$ CIHR Development of a quality of life instrument for homeless persons and street youth.General Internal Med. Studney Clinical Trial 3,335$ Sanofi-Synthelabo Canada Inc. CHARISAM Protocol EFC4505: CHARISMA - Clopidogrel for High Atherothrombotic Risk and Ischemic

Stabilization, Management and AvoidanceGeneral Internal Med. Studney Clinical Trial 5,250$ Aventis Pharma Inc

HOE 901/3502: Open-Label, Multicentre, Randomized Study to Assess an Early Insulization Strategy with Insulin Glargine vs a Standard Oral Strategy in the Management of Type 2 Diabetes.

General Internal Med. Studney Clinical Trial 13,063$ Novartis Pharmaceuticals Canada Inc CTR 1476G2305

Protocol CTR1476G2305: Multicenter Double-Blind Randomized Placebo-Controlled Parallel-Group Study to Evaluate the Safety and Efficacy of Trileptal in Patients with Neuropathic Pain Due to Diabetic Neuropathy

General Internal Med. Sunderwood Grant 5,000$ Dean of Medicine: Strategic Teaching Initiative Ambulatory medicine curriculum development

General Internal Med. Van Eeden Grant 1,500$ UBC Killam Faculty Research Fellowship Role of multipotential stem cells in the resolution of lung inflammation

General Internal Med. Van Eeden Grant 22,500$ BC Lung: Project Grant Monocyte recruitment with pneumoniaGeneral Internal Med. Van Eeden Grant 29,250$ CIHR: New Investigator Award (CIHR Scholarship) Atherosclerosis and atmospheric air pollution

General Internal Med. Van Eeden Grant 39,697$ WGCF: William M. Thurlbeck Prize William Thurlbeck Distinguished Researcher

General Internal Med. Van Eeden Grant 55,584$ H&SFBC: Research Air pollution induced atherogenesisGeriatric Medicine Beattie Contract 15,200$ CIHR: Operating Grant MOP-57686 in collaboration

with: University Health NetworkCanadian Alzheimer's disease quality of life study

Geriatric Medicine Beattie Grant 48,995$ ASC: Research Grant 02-51 CSHA-BC Cohort Linkage: Characterization, predition and costs of health services.Geriatric Medicine Meneilly Clinical Trial 6,106$ Servier Canada Protocol IC4-5702-001-CAN: Randomized Double-Blind Active-Controlled Parallel-Group

Multicentre Study of the Efficacy & Safety of Oral Gliclazide Modified Release Compared to Oral Glyburide in Elderly Type 2 Diabetic Patients

Geriatric Medicine Meneilly Clinical Trial 32,200$ Novo-Nordisk Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects with Type 2 Diabetes

Geriatric Medicine Meneilly Clinical Trial 35,000$ Novo-Nordisk Effect of NovoRapid Insulin vs Human Regular Insulin on Post-Prandial Hyperglycemia Elderly Subjects with Type 2 Diabetes

Geriatric Medicine Meneilly Contract 7,069$ Servier Canada Service Component: Randomized Double-Blind Active-Controlled Parallel-Group Multicentre Study of the Efficacy & Safety of Oral Gliclazide Modified Release Compared to Oral Glyburide in Elderly Type 2 Diabetic Patients

Geriatric Medicine MeneillyGrant

74,737$ Cdn Diabetes Assoc: Charles H. Best Fund/Grant-in-Aid

Diabetes in the Elderly

Geriatric Medicine Meneilly Grant 284,659$ UBC Overhead Recovery Research overhead and royalties





Geriatric Medicine MeneillyGrant

231,969$ Canadian Institutes of Health Research Genomics, Genetics and Gerontology (G3): A Multidisciplinary Team for the Study of Healthy Aging

Hematology Hogge Clinical Trial 6,057$ Janssen-Ortho Inc. Protocol R115777-INT-21: Open-Label Phase 2 Study of the Farnesyl Transferase Inhibitor Zarnestra (R115777) as Postconsolidation Therapy for Acute Myeloid Leukemia (AML) in Subjects 60 Years and Older

Hematology Humphries, Keith Grant 2,500$ MSFHR: Doctoral Trainee Research Award 111-BM:Gurevich, Rhonna

The Role of Homeobox Transcription Factors in Hematopoietic Stem Cell Function.

Hematology Humphries, Keith Grant 18,000$ MSFHR: Postdoctoral Trainee Fellowship STPDF 163021 Fellow: Hirose, Koichi

Molecular mechanisms linking Hox transcription factors to leukemia

Hematology Lansdorp Grant 1,167$ MSFHR: Doctoral Trainee Research Award STPHD067021 (Fellow: Cheung, Iris)

Molecular mechanisms of genomic instability and telomere shortening in Dog-1 mutants

Hematology Lansdorp Grant 1,422$ Beckman Coulter Canada Inc. Stem Cell Centre

Hematology Lansdorp Grant 3,000$ CFI Infrastructure Operating fund 3857 CFI Infrastructure Operating Funds - Stem Cell Centre - Centre Share

Hematology Lansdorp Grant 5,000$ CIHR: Canadian Graduate Scholarships - Doctoral Award CGD 65038 (Fellow: Cheung, Iris)

Molecular mechanism of genome stability and telomere shortening in dog-1 mutants

Hematology Lansdorp Grant 15,052$ Coherent Laser Group Stem Cell Centre

Hematology Lansdorp Grant 38,000$ CIHR: Postdoctoral Fellowship (Baross, Agnes)MFE-47697

Role of ataxia telangiectasia (ATM) gene in telomere function

Hematology Lansdorp Grant 45,475$ Innovative Directions Stem Cell Centre

Hematology Lansdorp Grant 57,500$ CFI Infrastructure Operating fund 3857 CFI Infrastructure Operating Funds - Stem Cell Centre - OperationsHematology Lansdorp Grant 113,500$ CIHR: Operating Grant MOP 38075 Replicative Shortening of Telomeres in Human CellsHematology Lansdorp Grant 260,860$ Cytopeia, Inc. Stem Cell Centre

Hematology Lavoie Clinical Trial 45,000$ Hoffmann-La Roche Ltd (Canada) Oral Valganciclovir Versus Intravenous Ganciclovir as Pre-emtive Therapy in Allogenic blood and Marrow Transplant with CMV Viremia.

Hematology Nevill Clinical Trial 700$ SangsStat Canada Ltd. SMC-101-1020: An OpenLabel Prospective Stratified Randomized Controlled Multicenter Phase IIB Study of the Impact of Thymoglobin Therapy on Transfusion Needs of Patients..SMC-101-1022 A Three Year Evaluation of the Overall and Leukemic fre.

Hematology Nevill Grant 10,000$ VHHSC: Interdisciplinary Grant Pilot Study of Cyclosporine Pharmacokinetic Monitoring in Allogeneic Bone Marrow

Hematology Schrader Grant 39,000$ MSFHR: Postdoctoral Trainee Fellowship 32-BM:Schubert, Peter Structure-function relationship of the GTP-exchange factor smg GDS and its role in breast cancer.

Hematology Schrader Grant 40,000$ NCE/Protein Engineering: Research Pence P3 Deg4 Pence P3 Deg4

Hematology Schrader Grant 129,092$ CIHR: Operating Grant MOP-14348 Molecular characterization of the M-Ras pathwayHematology Schrader Grant 200,000$ Canada Research Chair Tier I (CIHR) Canada Research Chair - John ScraderHematology Shepherd Clinical Trial 3,400$ Novartis Pharmaceuticals Canada Inc A phase III study of ST1571 versus Interferon-a (IFN-A) combined with Cytarabine (Ara-C0 in

patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)

Hematology Smith Grant 300,000$ CFI: Canada Research Chairs Infrastructure Fund 201334

Flow cytometric high throughput screening device for functional genomics research

Hematology Smith Grant 100,000$ Canada Research Chair: Tier II (CIHR) 950-01-2053 (Fellow: Smith, Clayton)

Canada Research Chair in cell therapies for Dr. Clayton Smith





Hematology Vickars Clinical Trial 700$ Aeterna Laboratories Inc Neovastat (AE-941) in refractory and early relapse multiple myeloma patients

Hematology Vickars Clinical Trial 2,200$ National Cancer Institute of Canada A comparative study of dexamethasone vs. prednisone (both in combo with melphalan) as induction therapy in untreated symptomatic myeloma with an additional assessment of dexamethasone vs. no additional treatment as maintenance therapy

Hematology Vickars Clinical Trial 3,300$ Sanofi-Synthelabo Canada Inc. The Van Gogh-DVT trial, a multicenter,international, randomized, open-label,assessor-blind,non-inferiority study comparing the efficacy and safety of once weekly subcutaneous SanOrg34006 with the combination of(LMW) Heparin and vitamin K an

Hematology Vickars Clinical Trial 9,682$ GlaxoSmithKline ThromboEMbolism prevention efficacy and safety trial (TEMPEST): A double-blind four-week study to assess the efficacy, safety and tolerability of SB 424323 in the extended prophylaxis of patients following total hip arthroplasty

Hematology Vickars Clinical Trial 19,715$ Leo Pharmaceutical Research Fdn A phase II, multicentre, randomised, open-label prospective study to evaluate Tinzaparin vs unfractionated heparin in subjects who are receiving long-term warfarin and require parenteral anticoagulation after the discontinuation of warfarin

Hematology Vickars Clinical Trial 20,870$ AstraZeneca LP Optimization of dose of H 376/95 (Oral Direct Thrombin Inhibitor) compared to Warfarin (Coumadin(R)) for the prevention of venous thromboembolism following total knee arthroplasty (TKA)

Hematology Vickars Clinical Trial 32,388$ Asahi Kasei America, Inc. A multicentre, open-label, dose response (phase IIa) study of ART-123 (recombinant human soluble thrombomodulin) by subcutaneous injection in the prevention of postoperative venous thrombosis in patients undergoing elective, unilateral tota

Hematology Vickars Grant 5,600$ McMaster University Multi-Centre Chart Audit of the Utilization of Risk Assessment and of Prophylaxis of Venus Thromboembolism in Acutely III Medical Patients In Canada

Hematology Vickars Grant 10,500$ National Cancer Institute of Canada A phase II study of oral Fludarabine Phosphate in patients with previously untreated B-cell chronic lymphocytic leukemia (CL.2)

Infectious Diseases Av-Gay Grant 1,000$ Pulmonox Medical Inc. Role of cholesterol in tuberculosis infection

Infectious Diseases Av-Gay Grant 25,000$ BC Lung/CIHR Investigator JBH: Av-Gay, Yossef Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary).

Infectious Diseases Av-Gay Grant 25,000$ CIHR: New Investigator Award JBH - 47862 (CIHR Scholarship: Av-Gay, Yossef)

Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary).

Infectious Diseases Av-Gay Grant 30,000$ BC Lung: Project Grant Mycothiol dependent isoniazid resistance in Mycobacterium tuberculosis

Infectious Diseases Av-Gay Grant 40,850$ CIHR: Operating Grant III 64950 in collaboration with: Institute of Infection and Immunity (CIHR)

Mycothiol dependent detoification system in Mycobacteria

Infectious Diseases Av-Gay Grant 50,000$ MSFHR: Sars Accelerated Vaccine Initiative PJ-SAV-011

High-throughput cloning and expressin of SARS U576proteins

Infectious Diseases Av-Gay Grant 50,000$ Various Sources: (Fellow: Av-Gay, Yossef) VH SCIENTIST AWARD; TB VETS - TB Research

Infectious Diseases Av-Gay Grant 69,736$ CIHR: Operating Grant Molecular Analysis of Mycobacterium Tuberculosis Protein Kinases and Phosphates

Infectious Diseases Av-Gay Grant 90,500$ NCE/Canadian Bacterial: Research Mycobacterium tuberculosis protein kinases and phosphatases as nobel drug targets

Infectious Diseases Brunham Grant 210,438$ NIH/U Washington Chlamydia an gonococcal infection: immunobiology in female repro. TractInfectious Diseases Brunham Grant 44,000$ Aventis Genetics & immunology of a virulence-associated bacteriophageInfectious Diseases Brunham Grant 121,470$ CIHR - Operating immunobiology of Chlamydia trach. InfectionInfectious Diseases Brunham Grant 46,500$ CIHR - Industry DNA vaccine for Chlamydia trach. InfectionInfectious Disease Brunham Grant 150,000$ Aventis Pasteur Project 2 - DNA vaccine for

Infectious Diseases Burdge Clinical Trial 17,131$ Various Pharmaceutical Companies Evaluation of SQ32,756 (BVaraU) versus Acyclavir in the Treatment of Localized Herpres Zoster in HIV infected patients

Infectious Diseases Cherkasov Grant 30,000$ VHHSC: Scholar Award (Fellow: Cherkasov, Artem) Bioinformatics study of microbial pathogens

Infectious Diseases Cherkasov Grant 25,000$ Genome Canada - salary support Bioinformatics study of microbial pathogens

Infectious Diseases Chow Grant 500$ MRC: MD/PhD Studentship (Hung, Ryan) Protective immunity in toxic shock syndrome





Infectious Diseases Chow Grant 20,000$ MRC: MD/PhD Studentship (Hung, Ryan) Protective immunity in toxic shock syndrome

Infectious Diseases Chow Grant 500$ MRC: MD/PhD Studentship ST-59025-AP010471(Lee, Jimmy)

Phagosome biogenesis

Infectious Diseases Chow Grant 20,000$ MRC: MD/PhD Studentship ST-59025-AP010471(Lee, Jimmy)

Phagosome biogenesis

Infectious Diseases Chow Grant 500$ MRC: MD/PhD Studentship (Rauh, Michael) MMP-38301

Cytokine-mediated signal transduction in leukemia

Infectious Diseases Chow Grant 20,000$ MRC: MD/PhD Studentship (Rauh, Michael) MMP-38301

Cytokine-mediated signal transduction in leukemia

Infectious Diseases Chow Grant 500$ CIHR: Doctoral Research Awards (Kalyan,Shirin) MDR-46129

Function of gamma/delta T cells in modulating the immune response in the pathogenesis of superantigen-secreting S. aureus

Infectious Diseases Chow Grant 20,000$ CIHR: Doctoral Research Awards (Kalyan,Shirin) MDR-46129

Function of gamma/delta T cells in modulating the immune response in the pathogenesis of superantigen-secreting S. aureus

Infectious Diseases Chow Grant 500$ MRC: MD/PhD Studentship MMP-40924(Yong,Paul) Chromosomal abnormalities in reproduction failure and development

Infectious Diseases Chow Grant 20,000$ MRC: MD/PhD Studentship MMP-40924(Yong,Paul) Chromosomal abnormalities in reproduction failure and development

Infectious Diseases Chow Grant 500$ MRC: MD/PhD Studentship (Sheldon,Claire) MMP-38300

Neuronal pH: Regulation in health and disease

Infectious Diseases Chow Grant 20,000$ MRC: MD/PhD Studentship (Sheldon,Claire) MMP-38300

Neuronal pH: Regulation in health and disease

Infectious Diseases Chow Grant 500$ CIHR: MD/PhD Studentship (Tan, Clara C-H) MMP-48141

The regulation of transcription factors by integrin kinase in cancer cells

Infectious Diseases Chow Grant 20,000$ CIHR: MD/PhD Studentship (Tan, Clara C-H) MMP-48141

The regulation of transcription factors by integrin kinase in cancer cells

Infectious Diseases Chow Grant 500$ CIHR: MD/Phd Program Studentship (Liam Brunham) MMP-58293

Identification and validation of genes modulating LDL cholesterol in humans

Infectious Diseases Chow Grant 20,000$ CIHR: MD/Phd Program Studentship (Liam Brunham) MMP-58293

Identification and validation of genes modulating LDL cholesterol in humans

Infectious Diseases Chow Grant 500$ CIHR: MD/PhD Program Studentship (Bryan Coburn) MMP-58313

The pathogenics of salmonella infection

Infectious Diseases Chow Grant 20,000$ CIHR: MD/PhD Program Studentship (Bryan Coburn) MMP-58313

The pathogenics of salmonella infection

Infectious Diseases Chow Grant 500$ CIHR: MD/Phd Program Studentship MMP-62317 (Weber, Amy)

Health Status & access to care among a population of urban youth

Infectious Diseases Chow Grant 20,000$ CIHR: MD/Phd Program Studentship MMP-62317 (Weber, Amy)

Health Status & access to care among a population of urban youth

Infectious Diseases Chow Grant 98,020$ NCE/Canadian Bacterial: Research Phase III: D4: Diagnosis of Intracellular Pathogens in Community-Acquired Pneumonia HSP60 Gene Sequences

Infectious Diseases Chow Grant 98,278$ CIHR: Operating Grant MT-7630 Pathogenesis of Staphylococcal Toxic Shock Syndrome

Infectious Diseases Chow Grant 20,000$ VCHRI Supplement to CIHR Strategic Training UBC Training program for translational research in infectious diseasesInfectious Diseases Chow Grant 300,000$ CIHR/Strategic Training: Strategic Training Program

Grant STI-63299UBC Training program for translational research in infectious diseases

Infectious Diseases Grigg Grant 25,000$ MSFHR: Matching Establishment Grant C1-SCH-20(01-2)

Molecular basis of toxoplasma pathogenesis

Infectious Diseases Grigg Grant 30,000$ VHHSC Scholar Award (Fellow: Grigg, Michael) Molecular Basis of Toxoplasma Pathogenesis

Infectious Diseases Grigg Grant 37,500$ MSFHR: Establishment Grant C1-SCH-20(01-2) Molecular basis of toxoplasma pathogenesis





Infectious Diseases Grigg Grant 46,408$ CIHR: Operating Grant MOP-64388 in collaboration with: Institute of Infection and Immunity (CIHR)

Toxoplasma surface antigens and immunity

Infectious Diseases Grigg Grant 80,000$ MSFHR: Career Investigator Program (C1-SCH-20(01-2) (Fellow: Grigg, Michael)

Molecular basis of Toxoplasma Pathogenesis

Infectious Diseases Grigg Grant 31,700$ NSERC Regulation of gene expression & genetic diversity of Toxoplasma

Infectious Diseases Harrigan Grant 2,000$ MSFHR: Doctoral Trainee Research Award STPHD60021 (Fellow: Brumme, Zabrina)

Factors impeding the success of HIV antiretroviral therapy today: genetic variation, viral evolution and drug resistance, and cellular reservoirs of HIV

Infectious Diseases Harrigan Grant 5,000$ CIHR: Doctoral Research Awards (Fellow: Brumme, Zabrina)

An investigation into challenges faced in antiretroviral (anti-HIV) therapy today: human and viral genetic variation, HIV antiviral resistance and the existence of viral reservoirs

Infectious Diseases Harrigan Grant 12,667$ CIHR/Rx&D Research Program - Postdoctoral Fellowship DFE-43158 (Fellow: Alexander, Christopher)

Development and application of validated methodology utilising tandem mass spectrometry for the quantification of plasma antiretroviral drugs from patients with HIV and /or Hepatitis B or C

Infectious Diseases Harrigan Grant 50,000$ CIHR Populational study of HIV DNA levels, HIV drug resistance genotype… BC

Infectious Diseases Harrigan Grant 49,290$ Ontario HIV treatment network (OHTN) Development and clinical assessment of a new T-20 genotypic resistance assay

Infectious Diseases Harrigan Grant 19,195$ St Paul's Hospital Foundation Investigation of HIV viral load and genotype in HIV infected patients

Infectious Diseases Hmama Grant 25,000$ MSFHR: Establishment Grant CI-SCH-26(01-2) Matching Establishment Grant: Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors

Infectious Diseases Hmama Grant 37,500$ MSFHR: Career Investigator Program C1-SCH-26(01-2)

Establishment grant: Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterium virulence factors

Infectious Diseases Hmama Grant 45,000$ MSFHR: Career Investigator Program C1-SCH-26(01-2) (Fellow: Hmana, Zakaria)

Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors.

Infectious Diseases Hmama Grant 58,500$ CIHR: New Investigator Award (CIHR Scholarship: Hmama, Zakaria)

Cell signaling regulating mycobacterial-macrophage interactions

Infectious Diseases Hmama Grant 76,827$ CIHR: Operating Grant MOP-43891 Cell signaling regulating mycobacterial-macrophage interactions

Infectious Diseases Hmama Grant 70,000$ TB VETS/VH FOUNDATION TB Research

Infectious Diseases Lee Grant 2,000$ MSFHR: Doctoral Trainee Research Award # 57(02-1)BM: Jimmy LEE (Res/Trav)

Role of Distinct P13-Kinase Isoforms in Regulating Phagocytosis and Phagsome Maturation.

Infectious Diseases Montaner Clinical Trial 662$ Abbott Laboratories, Limited (Canada) A phase IV long-term safety surveillance study of subjects enrolled in the M98-863 study (Protocol M01-305)

Infectious Diseases Montaner Clinical Trial 700$ Various Pharmaceutical Companies The Canadian Women's HIV Study - A study of the relationship between human papilloma virus infection, human immunodeficiency virus infection and cervical disease using cross-sectional, cohort and descriptive methodologies

Infectious Diseases Montaner Clinical Trial 2,000$ Hoffmann-La Roche Ltd (Canada) A phase III open-label, randomized, active-controlled study assessing the efficacy and safty of T-20/Ro 29/9800 (HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, in patients with prior experience and/or documented resistance to each of the class of approved antiretroviral (NTRI, NNRTI & PI)

Infectious Diseases Montaner Clinical Trial 2,000$ Hoffmann-La Roche Ltd (Canada) Open-label safety study of T-20 in patients with advanced HIV disease who are unable to construct a viable antiiral regimen (NV16391)

Infectious Diseases Montaner Clinical Trial 2,185$ Chiron Corporation A phase III multicenter randomized study of the biological and clinical efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT)

Infectious Diseases Montaner Clinical Trial 7,481$ Hoffmann-La Roche Ltd (Canada) A randomized, open-label, multicenter, pahse III, three arm study evaluating the efficacy and safety of Pegylated-interferon a-2a(Ro25-8310) monotherapy versus combination therapy of interferon a-2a(Ro22-8181) with Ribavirin for 48 weeks





Infectious Diseases Montaner Clinical Trial 8,250$ Bristol-Myers Squibb Company (Cda) A study to compare long-term safety and tolerability of Stavudine (d4T) extended release (ER) versus conventional (immediate release, IR) formulations, each in combination with Lamivudine (3TC) and Efavirenz (EFV) in subjects who have completed BMS studies AI455-096 and AI455-099

Infectious Diseases Montaner Clinical Trial 8,622$ Boehringer Ingelheim (Canada) Ltd. An open-label,randomized,parallel-group pharmacokinetics trial of tipranavir/ritonavir(TPV/RTV),alone or in combination with RTV-boosted saquinavir(SQV),amprenavir(APV)or lopinavir(LPV),plus an optimised background regimen,in multiple antir

Infectious Diseases Montaner Clinical Trial 9,910$ Boehringer Ingelheim (Canada) Ltd. Randomized,open-label,comparative safety and efficacy study of tipranavir boosted with low-dose ritonavir (TPV/RTV)versus genotypically-defined protease inhibitor/ritonavir(PI/RTV)in multiple antiretroviral drug-experienced patients (RESIST)

Infectious Diseases Montaner Clinical Trial 16,450$ CIHR/Rx&D: Research Program - Clinical TrialsDCT-51595

Randomized, open-label study of continued stavudine vs. abcavir substitution with or without riboflavin and thiamine supplementation in patients with elevated lactic acid while on stavudine-based therapy.

Infectious Diseases Montaner Clinical Trial 27,283$ CIHR/Rx&D: Research Program - Clinical TrialsDCT-48206

An Open Label, Randomized Study to Evaluate the Antiretroviral Effect, Tolerability, Safety and Pharmacokinetics of Squinavir SGC/Ritonavir QD vs. Indinavir/Norvir BID in HIV Infected Patients.

Infectious Diseases Montaner Clinical Trial 167,167$ GlaxoSmithKline Randomized, open label study of continued stavudine vs abacavir substitution with or without riboflavin and thiamine supplementation in HIV-infected patients who have elevated venous lactic acid while on stavudine-based therapy

Infectious Diseases Montaner Clinical Trial 245,699$ Bristol-Myers Squibb Company (Cda) Prospective evaluation of changes in peripheral blood mitochondrial DNA among persons initiating antiretroviral therapy: Impact on time to therapy discontinuation, regimen change, AIDS and death

Infectious Diseases Montaner Grant 2,416$ Bristol-Myers Squibb Pharmaceutical Group (Cda) The safety and antiviral efficacy of Stavudine extended release formulation as compared to Stavudine immediate release formulation, each as part of potent antiretroviral combination therapy (Protocol AI455-099)

Infectious Diseases Montaner Clinical Trial 333,133$ Abbott Laboratories A pilot study of a nucleoside analogue reverse transcriptase inhibitor sparing regimen in antiretroviral-naive, HIV-infected patients

Infectious Diseases Montaner Grant 7,000$ Abbott Laboratories, Limited (Canada) A randomized controlled trial of once-daily tenofovir, 3TC and lopinavir/r versus remaining on the same regimen in HIV-infected patients virologically suppressed on their first PI-containing HAART regimen

Infectious Diseases Montaner Grant 16,450$ CIHR/Rx&D: Research Program - Clinical Trials Randomized, open-label study of continued stavudine vs. abcavir substitution with or without riboflavin and thiamine supplementation in patients with elevated lactic acid while on stavudine-based therapy

Infectious Diseases Montaner Grant 29,330$ Merck Frosst A probe study to evaluate HIV-1 specific cell mediated immune responses..

Infectious Diseases Montaner Grant 40,000$ CANFAR Improvement of cardiovascular disease risk factors with combination therapy of Omega-2 PUFAs and plant steroids in HIV

Infectious Diseases Montaner Grant 46,960$ CIHR: Operating Grant DOP 60118 Prospective evaluation of changes in peripheral blood mitochondrial DNA among persons initiating antiretroviral therapy: Impact on time to threrapy discontinuation, regimen change, AIDS and death

Infectious Diseases Montaner Grant 39,000$ MSFHR: Postdoctoral Trainee Fellowship STPDF250021 (Fellow:Wood, Evan)

Baseline HIV RNA and mortality after the initiation of HAART: exploring the mechanism that explains the association.

Infectious Diseases Montaner Grant 227,074$ Boehringer Ingelheim (Canada) Ltd. A pilot protocol to evaluate the effect of Nevirapine on biochemical markers of cardiovascular risk in HIV-infected individuals receiving a protease inhibitor based regimen

Infectious Diseases Montaner Grant 18,454$ St Paul's Hospital An open-label,comparative study to evaluate the short term antiviral efficacy of Nevirapine and Efavirenz in combination with d4T and 3TC (The 2NN study)





Infectious Diseases Montaner Grant 98,450$ Tibotec Pharmaceuticals Ltd A randomized, placebo-controlled phase II trial in HIV-1 infected NRTI, PI and NNRTI experienced subjects to evaluate the safety tolerability and efficacy of different doses of TMC 125 b.i.d. on top of an individually optimized antiretroviral therapy by means of a 3-stage dose-escalating design

Infectious Diseases Montaner Grant 48,960$ AGOURON Use of delavirdine as a PK enhancer in Salvage Therapy

Infectious Diseases Montaner Grant 2,267$ The International Antiviral Therapy Evaluation Center

Mycophenolate Mofetil in combination with HAART in therapy-naïve HIV- -infected adults with varying CD4+ T cell counts

Infectious Diseases Montaner Grant 9,227$ The International Antiviral Therapy Evaluation Center

An open-label comparative study to evaluate the antiviral efficacy and safety of Nevirapine & Efavirenz or both drugs combined in combination d4T and 3TC

Infectious Diseases Montaner Grant 22,750$ MSFHR: Postdoctoral Trainee Fellowship Adverse drug effects among persons using antiretroviral therapy for HIV disease and impact on treatment patterns

Infectious Diseases Montaner Grant 42,800$ GlaxoSmithKline A pilot study of mycophenolate among patients with human immunodeficiency virus (HIV) disease receiving abacavir-containing antiretroviral therapy regimens

Infectious Diseases Montaner Grant 3,745$ GlaxoSmithKline A Retrospective, Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects Who Developed Hypersensitivity Following Treatment with Abacavir (Protocol CNA30032)

Infectious Diseases Nandan Grant 82,162$ CIHR: Operating Grant MOP 38005 Molecular Mechanism of Leishmania PathogenesisInfectious Diseases Press Grant 25,000$ CTN/CIHR Postdoctoral Fellowship Associate Award

Infectious Diseases Rawat Grant 30,000$ BC Lung: Project Grant Mycothiol dependent genes involved in oxidative stress and detoxification in mycobateria

Infectious Diseases Reiner Grant 2,500$ Various Companies Infectious Diseases shared services donations Health Sciences

Infectious Diseases Reiner Grant 41,775$ Various Sources CFI proposal funding: Network biology of infections and immunity

Infectious Diseases Reiner Grant 123,147$ CIHR: Operating Grant MOP-8633 Monocyte Cell Regulation

Infectious Diseases Reiner Grant 30,000$ BC Lung: Project Grant Identification of novel mechanisms of tuberculosis pathogenesis using two-hybrid screening

Infectious Diseases Rekart Grant 48,886$ BCMSF: Research Grant BCM03-0096 Evaluation of the impact of mandatory HIV reportability in British Columbia

Infectious Diseases Rekart Grant 855,988$ CIDA STI/HIV/AIDS Prevention and care in S. Vietnam

Infectious Diseases Steiner Grant 21,733$ BWF: Career Awards in the Biomedical Sciences 992840.01

Isolation and characterization of an interleukin-8-releasing protein from enteroaggregative Escherichia coli

Infectious Diseases Steiner Grant 35,732$ CFI: Infrastructure Operating Fund 4453 CFI Infrastructure Operating Fund

Infectious Diseases Steiner Grant 52,460$ CIHR: Operating Grant MOP-64355 in collaboration with: Institute of Infection and Immunity (CIHR)

Mechanisms of innate immune signaling by enteroaggregative Escherichia coli flagellin

Infectious Diseases Stiver Clinical Trial 6,369$ Various Pharmaceutical Companies AI411-227 in collaboration with: Innovus Inc., Pharmacia (Canada) Inc., SmithKline Beecham Pharma Inc. (Canada), Janssen-Ortho Inc., Parke-Davis Pharmaceuticals, Bristol-Myers Squibb Company (Cda), Pharmacia & Upjohn Inc, Viropharma Incorporated

The Safety and Efficacy of Cefepime versus Ceftriaxone in the Treatment of Non-hospital Acquired Pneumonia in the Elderly

Infectious Diseases Stiver Clinical Trial 21,091$ ID Biomedical in collaboration with: PPD Development

IDB 13007: Study to Estimate the Protective Efficacy Against Community-Acquired Epidemic Influenza of Two Alternative Dosing Regimens of FlulNsure a Proteosome Trivalent Influenza Vaccine Administered Intranasally to Healthy Adults 18 to 64

Infectious Diseases Stiver Clinical Trial 25,000$ Janssen-Ortho Inc. Study of the impact of Community Acquired Respiratory Virus Disease in Bone Marrow and Solid Organ Transplant Patients

Infectious Diseases Tyndall Grant 200,000$ CIHR Illicit opiate addition, treatment and policy in Canada

Infectious Diseases Tyndall Grant 45,030$ CIHR Role of injection drug use and Hepatitis C infection on tolerability of HAART

Infectious Diseases Tyndall Grant 200,000$ VCHA Community health and safety evaluation project





Infectious Diseases Tyndall Grant 490,000$ VCHA Scientific evaluation of the supervised injection site - SESIS

Infectious Diseases Tyndall/Palepu/Kerr Grant 36,446$ CIHR Feasibility study for a safe injection facility in the downtown eastside of Vancouver

Infectious Diseases Tyndall Grant 200,000$ Ontario HIV Network (OHTN) Post marketing surveillance of adverse events due to antiretroviral therapy

Medical Oncology Chi, Kim Nguyen Agreement 377,720$ US Army DAMD17-02-0226, PC011011 In collaboration with: OncoGenex

A Phase 1/11 study of combination neoadjuvant hormone therapy and weekly OGX-011 (Clusterin Antisense Oligonucleotide) prior to radical prostatectomy in patients with prostate cancer

Medical Oncology Gelmon Grant 22,500$ BC Lung: Project Grant A phase I study EF5 and 18F-EF5 in non-small cell lung cancer

Medical Oncology Klasa Grant 204,786$ Lymphoma Research Foundation (USA) New Molecular Targets in Mantle Cell Lymphoma

Medical Oncology Lumphoma Research Group

Grant 957,610$ Lymphoma Research Foundation (USA) New Molecular Targets in Mantle Cell Lymphoma

Nephrology Chiu Clinical Trial 8,722$ AstraZeneca Canada Inc A double-blind,randomised,dose-ranging,multi-centre,phase IIIb study to evaluate the efficacy and safety of high doses of candesartan cilexetil(Atacand)on the reduction of proteinuria in the treatment of subjects with hypertension and moder

Nephrology Copland Clinical Trial 1,000$ AMGEN Canada Inc. NESP 20000182 A Study evaluating the initiation and Titration of fixed dosed of Novel Erythropoiesis stimulating protein (NESP) in Therapy in subjects with End-Stage Renal Disease"

Nephrology Duncan Clinical Trial 35,000$ AstraZeneca Canada Inc 4522IL/0096 (AURORA): Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: An Assessment of Survival & Cardiovascular Events: Double-Blind Randomized Multicentre Phase IIIb Parallel-Group Study to Compare the ....

Nephrology Duncan Observational 90,000$ Ortho-Biotech An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) in Among Patients Receiving Epoetin Alfa Therapy or Other Erythropoietins (Amendment 1 to Protocal EPO-IMU-401) and (Protocol EPO-imu-402), Phase IV Safety Surveillance Program to conduct serolgoic testing for anti-erythopoietin antibodies and prospectively monitor the incidence of Pure Red Cell Aplasia (PRCA) in patients receiving epoetin-alpha therapy.

Nephrology Duncan Clinical Trial 50,000$ Boehringer A prospective, randomised, double-blind, double-dummy, forced-titration, multicentre, parallel group, one year treatment trail to compare MICARDIS (telmisartan) 80mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study)

Nephrology Gill Grant 50,000$ Kidney Foundation of Canada Kidney Transplant RejectionNephrology Gill Grant 45,000$ Kidney Foundation of Canada - Biomedical

ScholarshipKidney Transplant Rejection

Nephrology Gill Grant 35,000$ BC Transplant Foundation - Michael Smith Operating Grant

Transplant Rejection Pilot Project

Nephrology Gill Grant 75,000$ BC Transplant Foundation - Michael Smith Live Anonomous Donor Kidney Transplanation

Nephrology Gill Grant 45,000$ Novartis A one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY combined with reduced-dose or full-dose Neoral® and corticosteroids versus mycophenolate mofetil (MMF, CellCept®) combined with full-dose Neoral® and corticosteroids, in de novo adult renal transplant recipients

Nephrology Jung Clinical Trial 2,729$ AstraZeneca UK Limited A study to evaluate the use of rosuvastatin in subjects on regular hemodialysis: An assessment of survival and cardiovascular events (AURORA)(4522IL-0096) A double-blind, randomised,multicentre,phaseIIIb,parallel-group study to compare the

Nephrology Keown Clinical Trial 60,000$ Novartis Pharmacokinetic Modeling and Therapeutic Monitoring of Immunosuppression

Nephrology Landsberg Clinical Trial 10,000$ Novartis CRAD001 A Multicentre, Single Arm, Open Label, Pilot Study of the Efficacy and Safety of RAD in de novo Renal Transplant Recipients at Immunological High Risk of Rejection





Nephrology Landsberg Clinical Trial 20,000$ Novartis LES EUR-02 Alert European Multicentre, Randomized, Double-Blind, Placebo Controlled Study of the Long Term Effects of Fluvastatin (Lescol) on Major Adverse Cardiac Events (MACE) and Progression of Chronic Transplanted Dysfunction in Renal Transplanted

Nephrology Landsberg Clinical Trial 20,000$ Wyeth-Ayerst Research Sirolimus 310 A Randomized, Open-Label Study of Continuous Therapy with CsA and Sirolimus vs Induction with CsA and Sirolimus followed by Continuous Therapy with Sirolimus in Renal Allograft Recipients

Nephrology Landsberg Clinical Trial 15,000$ Roche Canada CAESEAR The Use of Daclizumab (Zenapax TM) and Mycophenolate Mofetil (CellCept ®) in Combination With Corticosteroids and Neoral® (Low Dose versus Low Dose Followed by Complete Withdrawal) to Optimize Renal Function in Recipients of Renal

Nephrology Landsberg/ Shapiro Clinical Trial 50,000$ Fujisawa Canada Inc. FKC-008 The Effect of Treatment of Subclinical Rejection on Renal Histology and Graft Function in Renal Transplant Patients Receiving Tacrolimus and Mycophenolate Mofetil

Nephrology Landsberg Clinical Trial 54,000$ Wyeth-Ayerst Sirolimus 316: A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft receipients

Nephrology Levin Clinical Trial 883$ Janssen-Ortho Inc. Double blind study to assess the impact of normalizatin of hemoglobin compared to partial correction of hemoglobin with eprex/erypo erythropoietinin early hemodialysispatients (RWJ-22512)

Nephrology Levin Clinical Trial 2,939$ AMGEN Canada Inc. A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of a calcimimetic agent (AMG 073) in subjects with secondary hyperparathyroidism of chronic renal insufficiency

Nephrology Levin Clinical Trial 19,014$ Hoffmann-La Roche Ltd (Canada) An open-label, randomized, multicentre, multiple dose trial to investigate the efficacy and safety of subcutaneous injections of RO 50-3821 at different dosing intervals in patients with chronic renal anemia who are not on renal replacement

Nephrology Levin Clinical Trial 95,959$ Janssen-Ortho Inc. A study to determine the impact of Hgb maintenance and other interventional strategies to prevent or delay the progression of left ventricular mass growth in subjects with early renal insufficiency

Nephrology Levin Grant 6,454$ Kidney Foundation of Canada Longitudinal study of atherosclerosis in renal disease - and - renal insufficiency and comorbid conditions: Focus of left ventricular hypertrophy and cardiac disease in patients with progressive renal disease. A Canadian multi centre study

Nephrology Levin Grant 7,500$ MSFHR:Postdoctoral Trainee Fellowship STPDF240021 (Fellow: Khan, Nadia)


Nephrology Levin Grant 43,083$ CIHR: Postdoctoral Fellowship MFE-63502 in collaboration with: Institute of Circulatory & Respiratory Health (CIHR)(Fellow: Khan, Nadia)


Nephrology Levin Grant 45,000$ Kidney Fdn: Biomedical Fellowship (Fellow: Stigant, Caroline)

C-Reactive protein levels and vascular access thrombosis in chronic hemodialiysis patients

Nephrology Levin Grant 45,000$ Kidney Fdn: Biomedical Fellowship (Fellow: Stevens, Lesley Ann)

The relationship of abnormalities in mineral metabolism to cardiovascular disease in end stage renal disease

Nephrology Levin Grant 105,000$ Kidney Foundation of Canada Care prior to dialysis: A multicentre prospective cohort study in renal insufficiency to assess the impact of elements of care on patient outcomes (CREDA)

Nephrology Levin Grant 135,506$ Various Sources NERC

Nephrology Quamme Grant 166,250$ CIHR: Operating Grant # MOP-53288 Studies of Renal Magnesium Transport.

Nephrology Shaprio Clinical Trial 10,000$ Fujisawa Canada Inc. FKC-003: TACROLIMUS Tarcolimus as Secondary Intervention vs Continuation of CsA in Patients at Risk for Chronic Renal Allograft Failure

Nephrology Shaprio Clinical Trial 4,600$ Novartis Pharmaceuticals ERL080A Multicentre, Double-Blind, Randomized, Parallel Group Study on Tolerability and Safety of ERL080A vs Mycophenolate Mofetil (CellCept) in Maintenance Renal Transplant Patients

Nephrology Shaprio Clinical Trial 12,000$ Bristol Myers Squibb Open Label Randomized, controlled, multiple dose study of efficacy and safety of BMS-224818 as part of a quadruple drug regimen in renal transplant recipients

UBC Department of Medicine 2 Annual Report 2003




Nephrology Shaprio Clinical Trial 20,000$ Fujisawa Canada Inv Phase III, randomized, open-label, comparative, multicentre study to assess the safety and efficacy of Profraf (Tacrolimus)/MMF, modified release (MR) tacrolimus/MMF & Neoral / MMF in de novo kidney transplant patients

Nephrology Wong Grant 30,000$ Show Chwan/VHHSC Fund Vasoactive peptides in congestive heart failure

Nephrology Wong Grant 25,000$ Canadian Apoptosis Research Foundation Accelerated neuronal aging caused by transient exposure to toxin

Neurology Devonshire Grant 7,000$ Amgen. Inc. MS COSTAR Data Entry for the Genetic Suseptibility to MS StudyNeurology Devonshire Clinical Trial 72,514$ Biogen, Inc C-1801 C-1801: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to

Determine the Safety and Efficacy of Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis.

Neurology Doudet Contract 82,150$ Titan Pharmaceuticals Inc. In vivo PET study of the effects of striatal implantation of Retinal Pigment Epithelial Cells in a primate model of Parkinson's Disease

Neurology Doudet Contract 52,805$ Merck & Co., Inc In vivo study of the NK1 receptors in an acute and a long term primate model of Parkinson's Disease

Neurology Doudet Grant 104,518$ MRC: Group Grant MOP-14535 DDMP Project 10: In vivo study of the effects of manipulations on the Neurology Eisen Clinical Trial 64,524$ Aventis Pharma Inc.

RP54274/CA1.401A Canadian Multicentre Phase IV Comparative Study of the Effect of Riluzole 50 mg Bid on the Survival of ALS Subjects Compared to Historical Controls - the CARE STUDY.

Neurology Eisen Clinical Trial 7,820$ Novartis Pharmaceuticals Canada IncProtocol CTCH346A 2211: A Randomized Double-Blind Placebo-Controlled Stratified Parallel-Group Multicentre Dose-Ranging Study Evaluating Four Oral Doeses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients with ALS

Neurology Eisen Grant 500$ Donations for Health Science Research General Neurology Research

Neurology Eisen Clinical Trial 230$ Various Pharmaceutical Companies Neuromuscular Diseases

Neurology Eisen Grant 230$ Donations for Health Science Research Neuromuscular Clinic

Neurology Eisen Clinical Trial 320,000$ Webster Foundation A Pilot Clinical Trial of Intravenous Infusion of Autologous Hematopoietic Progenitor Cells in Patients with Amyotrophic Lateral Sclerosis (ALS)

Neurology Feldman Clinical Trial 77,746$ GlaxoSmithKline Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimers Disease: the GenAda Study Protocol ALDHD2001/00013/00

Neurology Feldman Clinical Trial 6,000$ Sanofi-Synthelabo Canada Inc. Protocol EFC 5286: Phase II Multicentre Multinational Randomized Double-Blind Placebo-Controlled Efficacy, Safety and Tolerability Study of SR57667B in Patients with Mild to Moderate Alzheimer's Disease

Neurology Feldman Clinical Trial 7,108$ University of California, San Diego A randomized double blind, placebo controlled trial to evaluate the safety & efficacy of vitamin E and Donepezil HC1 (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer's disease.

Neurology Feldman Clinical Trial 15,600$ Pfizer Canada Inc. A2581078 A2581078 The LEADe Study: 80-week Randomized Multicenter Paralle-Group Double-Blind Study of the Efficacy & Safety of Atorvastatin 80mg + Acetylcholinesterase Inhibitor vs an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild …

Neurology Feldman Clinical Trial 9,685$ Janssen-Ortho Inc. GAl-INT-6: The safety and efficacy of Galantamine in the treatment of vascular and mixed dementia

Neurology Feldman Clinical Trial 13,740$ Boehringer Ingelheim (Canada) Ltd. Protocol 1198.052: Phase II Double-Blind Randomized Dose-Ranging Placebo-Controlled Multicenter Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer's Type

Neurology Feldman Clinical Trial 85,805$ Janssen-Ortho Inc. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with Mild cognitive Impairment (MCI) clinically at risk for clinically probable Alzheimer





Neurology Feldman Contract 195,000$ Various Pharmaceutical Companies ACCORD II - A longer term Assessment of cognitive Impairment and Dementia Syndromes with an Evaluation of Treatment Effectiveness

Neurology Feldman Grant 38,638$ VHHSC: VGH/UBC Fdn Special Opportunities Research Fund

A Serial Magnetic Resonance Study of Cognitively-Impaired-Not-Demented Patients and Controls

Neurology Feldman Grant 39,000$ MSFHR: Postdoctoral Trainee Fellowship 117(02-01) BM (Fellow: Hsiung, Ging-Yuek) Susceptibility genes and environment risk factors for Alzheimer's disease.

Neurology Feldman Grant 90,477$ ASC/Astra/CCNS/CIHR: Alzheimer Disease Biomedical Res. Grant 02-49 A serial magnetic resonance study of cognitively-impaired-not demented patients and controls

Neurology Feldman Grant 150,000$ Eisai Inc. ACCORD II: A Longer Term Assessment of Cognitive Impairment and Dementia Syndromes with an Evaluation of Treatment Effectiveness

Neurology Gibson Clinical Trial 4,000$ Bayer Corp Protocol 100538: Multicentre Randomized Double-Blind Placebo-Controlled Study to Evalutate the Efficacy and Safety of IGIV-Chromatography (IGIV-C) 10% Treatment in Subjects with Chronic Inflammatory Demyelinating Polyneuropathy

Neurology Gibson Clinical Trial 17,156$ Eli Lilly Canada Inc. Protocol B7A-MC-MBBR: LY333531 Treatment of Peripheral Neuropathy in Patients with Diabetes: A Phase 3 Pivotal Clinical Trial

Neurology Gibson Clinical Trial 17,686$ Eli Lilly Canada Inc. Protocol B7A-MC-MBCW: LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes

Neurology Hashimoto Clinical Trial 819$ Biogen Inc. C98-838 IN COLLABORATION WITH: Covance Clinical and Periapproval Services Inc.

An open label safety extension study of AVONEX (Interferon Beta-la) treatment in subjects who completed Biogen studies C95-812, C96-823 or C97-830

Neurology Hashimoto Clinical Trial 44,783$ Biogen Inc. Controlled High Risk AVONEX Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance CHAMPIONS C-850

Neurology Hashimoto Grant 860$ Donations for Health Science ResearchClinical Research for Multiple Sclerosis

Neurology Hooge Clinical Trial 17,165$ Ares-Serono International Inc. 21125, BB-IND 5371 An open label, randomized, multicentre, comparative, parallel group study of Rebit 44mcg administered three times per week by subcutaneous injection, compared with Avonex 30msg administered once per week by intramuscular injection.

Neurology Johnston Clinical Trial 13,203$ Sanofi-Synthelabo Canada Inc. Clopidogrel for high atherothrombotic risk and ischemic stabilization, managment and avoidence (CHARISMA)

Neurology Jones Clinical Trial 25$ Pfizer Canada Inc. Protocol 1008-112-141: Pregabalin BID Add-On Trial: A Randomized, Double-Blind, Parallel-Group, Placebo and Lamotrigine-Controlled, Multicenter Study in Patients with Partial Seizures.

Neurology Jones Clinical Trial 2,910$ UCB Pharma An Open-Label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg bid) at Individualized Doses Up To a Maximum or 4000 mg/day (or 80 mg/kg/day for Children and Adoles

Neurology Jones Clinical Trial 5,402$ UCB Pharma A double-blind, multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of adjunctive treatment with 3000 mg/day(pediatric target dose of 60mg/kg/day)oral levetiracetam (LEV) (166,250,and 500 mgtablets).....

Neurology Jones Clinical Trial 9,620$ Pfizer Canada Inc. Protocol 1008-157-181: Pregabalin BID Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures

Neurology Jones Clinical Trial 11,895$ Warner-Lambert Canada Inc. Pregabalin ann-on trial: A double blind, placebo controlled, multicentre study in patients with partial seizures. 1008-009

Neurology Jones Clinical Trial 21,374$ Pfizer Canada Inc. Protocol 1008-164: Pregabalin BID Open-Label, Add-On Trial: A Follow-On Study To Determine Long-Term Safety and Efficacy in Patients with Partial Seizures





Neurology Kastrukoff Clinical Trial 74,824$ Teva Neuroscience, GP 9008PROMISE - A multi national, multicentre double blind, placebo controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate in Primary Progressive Multiple Sclerosis

Neurology Kastrukoff Contract 6,000$ Chemokine Therapeutics Corp The immune response in Multiple Sclerosis

Neurology Kastrukoff Grant 200$ Donations for Health Science Research Virology ResearchNeurology Kim Contract 16,785$ UBC Offices of Research Services & Industry

LiaisonDesign and Construction of Neural Cell Populations for Brain Research

Neurology Krieger Grant 30,000$ VHHSC Clinical Investigator Award: (Fellow: Charles Krieger)

Modulation of Neuron Death by Protein Kinase C and Calcineurin in Amyotrophic Lateral Sclerosis.

Neurology Krieger Grant 27,500$ NSERC C-RGPIN 171372 Repetitive firing of sensory neurons

Neurology Lee Grant 24,890$ CIHR: Operating Grant MOP 42471 Studies on mechanisms of dyskinesia induced by pulsatile treatment with levodopa

Neurology Lee Grant 116,648$ MRC: Operating Grant Studies on the natural history and etiology of sporadic Parkinson's disease

Neurology Lee Grant 30,000$ VHHSC Scholar Award Studies on mechanisms of dyskinesia induced by pulsatile treatment with levodopa

Neurology Martzke Grant 7,930$ CIHR: Operating Grant MOP-62966 Neurobehavioral outcome following implantation of bilateral subthalmic nucleus stimulators in Parkinson's Disease

Neurology Martzke Grant 17,750$ VH Foundation Special Opportunities Research Fund Award

Neurobehavioral outcome following bilateral subthalamic nuclei brain stimulation

Neurology Martzke Grant 9,936$ Vancouver Hospital Interdisciplinary Research Grant Neurobehavioral outcome following thalamic DBS for chronic facial pain

Neurology Oger Clinical Trial 10,000$ Novartis Pharmaceuticals Canada Inc. Protocol CFTY720D2201: Double-Blind Randomized Placebo-Controlled Parallel-Group Multicenter Study Evaluating Safety Tolerability & Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients with Relapsing Multiple Sclerosis

Neurology Oger Clinical Trial 10,665$ Berlex Canada Inc. Protocol 306083: Double-Blind Randomized Multicentre Placebo-Controlled Parallel-Group Phase IIa Study to Evaluate the Safety & Tolerability of Oral Mesopram (ZK 117137) up to 1.0 mg/d for up to 12 Weeks in an Intraindividual Dose Escalat...

Neurology Oger Clinical Trial 19,110$ Aventis Pharmaceuticals Inc. HMR 1726D/2001 1) Phase II study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis with relapses.2) Evaluation of in-Vitro Cell Adhesion in MS Patients, Effect of Treatment with Teriflunomide (Sub-Study).

Neurology Oger Clinical Trial 35,675$ Neurocrine Biosciences Ltd. NBI-5788-0201 Protocol NBI-5788-0201: Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients with Relapsing-Remitting Multiple Sclerosis

Neurology Oger Clinical Trial 37,915$ Aventis Pharma Inc. HMR 1726/2002 Protocol HMR 1726D/2002: Extension of Protocol HRM 1726D/2002, A Phase II Study of the Safety & Efficacy of Teriflunomide (HMR 1726) in Multiple Sclerosis with Relapses

Neurology Oger Clinical Trial 51,002$ Biogen Inc C-867 Protocol C-867: Multicentre Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of Avonex (Interferon beta 1a) Administered Intramuscularly to Patients with Relapsing/Remitting Multiple Clerosis

Neurology Oger Clinical Trial 93,206$ Biogen Inc. Protocol C-862: Multicentre Prospective and Retrospective Long-Term Observational Study of Avonex and Rebif to Determine the Efficacy Tolerability and Safety in Subjects with Relapsing Multiple Sclerosis

Neurology Oger Contract 60,000$ Biogen, Inc (Fellow: Smythe, Penelope) Clinical fellowship for Dr. Penelope Smyth

Neurology Oger Grant 883$ Donations for Health Science Research Myasthenia Gravis Research

Neurology Oger Grant 2,000$ Donations for Health Science Research MS Studies

Neurology Oger Grant 5,472$ Donation Neuro-Immunology ResearchNeurology Oger Grant 16,619$ Multiple Sclerosis International Federation Adnan Al Araji: study visit





Neurology Oger Grant 25,000$ Berlex Canada Inc. Non-Adherence to the Beta-Interferons for Multiple Sclerosis in clinical practice: A British Columbia-wide study

Neurology Oger Grant 39,000$ MSSC: Postdoctoral Fellowships (Fellow: Tremlett, Helen)

MSSC Postdoctoral Fellowship - Dr. Helen Tremlett

Neurology Paty Contract 107,000$ Donations for Health Science Research MS COSTAR Data Entry for the Genetic Susceptibility to MS Study

Neurology Paty Contract 4,299,630$ Various Sources MS/MRI operating - research group

Neurology Paty Grant 10,800$ Dean of Medicine: Ludmila and Henry Zeldowicz Award (Fellow: Vorobeychik, Galina)

EEG abnormalities in patients with psychiatric problems

Neurology Paty Grant 105,703$ Donations for Health Science Research Health Science Research Donations.Neurology Pelech Grant 107,531$ MRC: Operating Grant MOP 38062 MAP kinase pathways in seastar oocyte cell cycle control

Neurology Ruth Grant 3,750$ CFI: Infrastructure Operating Fund 5034 CFI Infrastructure Operating Funds - Functional Imaging in Basic Biomedical Research - Centre Share

Neurology Ruth Grant 5,000$ CIHR: Workshops & Symposia MWS-64833 Functional imaging in basic biomedical research through microPet imaging

Neurology Ruth Grant 25,830$ MRC: Group Grant MT - 14535 DDMP Project 10: In vivo study of the effects of manipulations on the depaminergic synapse by PET

Neurology Ruth Grant 34,770$ CFI: Infrastructure Operating Fund 5034 CFI Infrastructure Operating Funds - Functional Imaging in Basic Biomedical Research Operations

Neurology Ruth Grant 57,361$ MRC: Multi-User Maintenance Grant MT-11806 Maintenance support for the UBC Siemens 953-31/B Poistron tomographNeurology Ruth Grant 516,368$ MRC: Group Grant MGC 36035 DDMP Core B: Positron Emission Tomography

Neurology Ruth Grant 779,010$ CTI Incorporated High Resolution Functional Imaging in Neurodegenerative Diseases

Neurology Spacey Grant 50,000$ VHHSC: Mentored Clinical Scientist Salary: Paroxysmal neurological disease: the role of the human P/Q type calcium channel

Neurology Stoessl Clinical Trial 49,450$ Smithkline Beecham Pharma Inc. (Canada) 101468/170

A non-interventional follow-up study to observe the long term outcome of Parkinson's Disease in patients who completed study SK & F 101468/056 or study SK&F 101468/125 (STUDY 101468/170)

Neurology Stoessl Clinical Trial 79,500$ Amgen, Inc 20020168-901 GDNF 20020168: PET Scanning in Association with a Multicentre Randomized Double-Blind Placebo-Controlled Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (Ipu) Infusion of Subjects with Idiopathic…

Neurology Stoessl Clinical Trial 164,140$ Kyowa Pharmaceutical, Inc 6002-US-005 in collaboration with: Lineberry Research Associates

6002-US-005: A 12 Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy or 40mg/day KW-6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy

Neurology Stoessl Contract 104,445$ US Natl Parkinson Fdn: Research National Parkinson Foundation, Centre of Excellence

Neurology Stoessl Grant 50,000$ MSFHR: James A. and Donna Mae Moore Endowment

Studies of patients with a high genetic risk of developing Parkinson's disease

Neurology Stoessl Grant 56,766$ MRC: Group Grant MT-14751 DDMP Project 11: Pharmacological studies in experimental models of dyskinesia

Neurology Stoessl Grant 127,761$ MRC: Operating Grant MT - 15126 (in collaboration with University of Wisconsin-Madison)

Studies on fluctuations in response to dopaminergic therapy

Neurology Stoessl Grant 200,000$ Canada Research Chair Tier I (CIHR) Canada Research Chair - A. Jon Stoessl

Neurology Stoessl Grant 646,708$ MRC: Group Grant MGC 36035 Degenerative Disorders of the Motor Pathways

Neurology Stoessl, A.J. Grant 178,000$ Pacific Parkinson's Research Institute Movement Disorder Clinic

Neurology Stoessl, A.J. Grant 208,000$ Various sources 16-017292-7 Movement Disorder Clinic

Neurology Teal Clinical Trial 1,400$ University of Ottawa The Registry of the Canadian Stroke Network





Neurology Teal Clinical Trial 4,000$ AstraZeneca Canada Inc Protocol SA-NXY-0007: Double-Blind Randomized Placebo-Controlled Parallel-Group Multicenter Phase IIb/III Study to Assess the Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

Neurology Teal Clinical Trial 4,525$ Yamanouchi USA Inc. ARTIST: A Multicentre Stratified Randomized Double-Blind Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Acti

Neurology Teal Clinical Trial 7,250$ University of Calgary Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence Trial

Neurology Teal Clinical Trial 45,884$ Sanofi-Synthelabo Canada Inc. Protocol EFC4505: (CHARISMA) Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance

Neurology Teal Clinical Trial 49,160$ Wake Forest University - School of Medicine Vitamin Intervention for Stroke Prevention

Neurology Teal Clinical Trial 82,238$ ONO Pharma USA, Inc 2506/INT0104: Randomized Double-Blind Placebo-Controlled Multi-Centre Study of the Effects of ONO-2506 IV Infusion on the Amelioration of Neurological Damage & Improvement of Stroke Assessment Scale Scores in Patients with Acute Ischemic St

Neurology Teal Clinical Trial 133,013$ Bayer Inc. A randomized double-blind, placebo-ctonrolled trial to Evaluate the efficacy, safety, tolerability, and pharmacokinetic/Pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke.

Neurology Thiessen Grant 274,235$ NCIC Terry Fox New Frontiers Initiative Grant Integrin Linked Kinase Inhibition as an Approach to Treating Malignant Gloimas

Neurology Traboulsee Clinical Trial 25,142$ Berlex Canada Inc. 304747 304747: Double-Blind Placebo-Controlled Randomized Parallel Group Multicenter Phase 3 Study to Evaluate the Safety Tolerability & Efficacy of 8 MIU Interferon Beta-1b (Betaseron) in Patients with a First Demyelinating Event Suggestive of MS

Neurology Tsui Clinical Trial 1,000$ Allergan Inc Protocol#191622-017-00 - Observational study of BOTOX use in Cervical Dystonia

Neurology Tsui Clinical Trial 15,698$ Novartis Pharmaceuticals Canada Inc. # CTCH346 0103

CTCH346 0103: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg & 20 mg daily) in Patients with Early Parkinson's Disease.

Neurology Tsui Clinical Trial 28,002$ Elan Pharmaceuticals Inc. AN072-401CD An Open Label Safety and Immunogenecity Study of MYOBLOC (NEUROBLOC; BOTULINIM TOXIN TYPE B) Injectable Solution in Patients with Cervical Dystonia.

Neurology Tsui Clinical Trial 32,835$ MERCK (Germany) in collaboration with: Monitoring Force USA, Inc.

Protocol EMR 62 225-006: Multicentre Multinational Randomized Double-Blind Placebo-Controlled Parallel-Group Dose-Finding Study to Investigate theAnti-Dyskinetic Efficacy & Safety of Sarizotan in Parkinson Patients with L-dopa-induced Dysk

Neurology Tsui Grant 12,074$ CIHR: Operating Grant MOP-15583 in collaboration with: Institute of Population and Public Health (CIHR)

Occupational Risk Factors in Parkinson's Disease

Neurology Wang Grant 32,000$ MSFHR: Postdoctoral Trainee Fellowship (Fellow: Wong, Tak Pan)

Modulation of ligand-gated receptors by G protein-coupled receptors

Neurology Wang, Yu Tian Grant 600$ CIHR: Doctoral Research Awards DD5 61947 In Collaboration With: Institute of Circulatory & Respiratory Health (CIHR) Fellow: Liu, Yitao

Ampar trafficking in models of cerebral ischemia

Neurology Wang, Yu Tian Grant 142,884$ Howard Hughes Medical Institute Protein-protein interaction mediates co-trafficking GPCR and ligand-gated ion channels

Neurology Wang, Yu Tian Grant 143,065$ CIHR Operating Grant AMPA receptor regulation and synaptic plasticity

Neurology Wang, Yu Tian Grant 171,021$ CIHR Operating Grant Regulation of postsynaptic expression of GABAA receptors

Neurology Wang, Yu Tian Grant 116,647$ Heart and Stroke Foundation of Ontario/BC & Yukon Depression of AMPA receptor-mediated excitation by insulin

Neurology Wang, Yu Tian Grant 238,420$ CIHR Group Grant Synaptic Structure and Function (one of six principal investigators)

Neurology Wang, Yu Tian Grant 78,000$ Canadian Network of Excellence in Stroke Research Pre-clinical studies on treatment of stroke with inhibitors of NMDA receptor-PSD95 interaction

Neurology Wang, Yu Tian Grant 397,400$ CIHR Group Grant The Synapse (one of eleven principle investigators)





Neurology Wang, Yu Tian Grant 70,000$ CIHR Investigator Award Postsynaptic regulation of neurotransmission

Neurology Wang, Yu Tian Grant 75,000$ MSFHR, Senior Scholar Establishment Award Postsynaptic regulation of neurotransmission

Neurology Wang, Yu Tian Grant 45,000$ MSFHR Senior Scholar (incentive award only due to the CIHR Investigator Award)

Postsynaptic regulation of neurotransmission

Neurology Wong, Milton Clinical Trial 24,964$ ONO Pharma USA, Inc A randomized, double-blind, placebo-controlled, parallel group, multi-center study of the effects of ONO-2505 intravenous on the improvement of strokes and improvement in the stroke assessment scales scores in patients with acute ishcemic sNeurology Wong, Milton Grant 715$ Hoffmann-La Roche Canadian Activase for stroke effectiveness study (Cases)

Neurology Woolfenden Clinical Trial 2,080$ Boehringer Ingelheim (Canada) Ltd. 599.6: Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy Tolerability & Safety of Crobenetine (BIII 890) (535mg iv infusion for 24 hrs) in 800 Patients with Acute Stroke of Moderate to Severe Intensity & Administ....

Neurology Woolfenden Clinical Trial 2,558$ NIH (US): Research Grant SONIA: Stroke Outcome and Neuroimaging of Intracranial Stenosis

Neurology Woolfenden Clinical Trial 4,410$ Endovasix Inc. Protocol EPAR II: Pivotal Study to Evaluate the Safety and Efficacy of the EPAR Therapy System in the Recanalization of Intracranial Arterial OcclusionsNeurology Woolfenden Clinical Trial 9,153$ University of Cincinnati Interventional Managment of Stroke (IMS) Study

Neurology Woolfenden Clinical Trial 42,657$ Emory University Hospital Warfarin Aspirin symptomatic intractranial disease (WASID) study

Neurology Woolfenden Clinical Trial 63,757$ Novo-Nordisk Protocol F7ICH-1371: Randomized Double-Blind Placebo-Controlled Multicentre Parallel Groups Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (Niastas/NovoSeven) in Acute Intracerebral Haemorrhage

Physical & Rehab Med Dawson, Andrew Clinical Trial 15,000$ BC Rehab Foundation Cardiovascular Fitness in Acute Stroke Patients

Physical & Rehab Med Dawson, Andrew Clinical Trial 36,740$ CIHR Postural Control in Stroke (2002-05)Physical & Rehab Med Dawson, Andrew Clinical Trial 80,000$ Heart & Stroke Foundation Exercise Programs in Stroke (2003-06)

Physical & Rehab Med Dhawan, Pankaj Clinical Trial 65,000$ Allergan Pharm. A multicentre, open label study of the safety of repeated doses Botulinum Toxin A (Botox) for the treatment of focal upper limb post-stroke spasticity.

Physical & Rehab Med Dhawan, Pankaj Gait Observational Study

21,000$ Neurostream Technologies Gait Observational Study in Stroke.

Physical & Rehab Med Dhawan, Pankaj Pilot Feasibilility Study

21,000$ Neurostream Technologies Pilot Feasibility Study of the neuro step system.

Physical & Rehab Med Townson, Andrea Clinical Trial 15,000$ BCNF Intramuscular Stimulation for Pain following SCI: A Retrospective Analysi

Physical & Rehab Med Townson, Andrea Clinical Trial 15,000$ BC Rehab Foundation Measuring Leisure Lifestyles for Indivisuals with Spinal Cord Injuries

Physical & Rehab Med Townson, AndreaYao, JenniferKoo, DavidWeeks, ClaireHughes, Barbara

Clinical Trial 10,346$ ACORDA Therapeutics SCI-F300: Double-Blind, Placebo-Controlled, 4 Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects with Moderate to Severe Spasticity Resulting from Chronic, Incomplete Spinal Cord Injury

Physical & Rehab Med Underwood Grant 15,000$ BC Rehab Foundation The effects of Prosthetic Alignment and Interface Materials in Minimizing Foot Pressure within Rotation plasty Prosthesis

Physical & Rehab Med Van Rijn Grant 585$ Dean of Medicine: Strategic Teaching Initiative The resident as a teacher/communicator

Physical & Rehab Med Van Rijn Grant 35,598$ Vancouver Coastal Health Authority Salary: Research Nurse

Physical & Rehab Med Weeks, Claire Koo, David

Clinical Trial undisclosed Pfizer Pharmaceuticals A multi-center, double-blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of Viagra in women who have female sexual arousal disorder resulting from a traumatic spinal cord injury.





Physical & Rehab Med Weeks, Claire, PITownson, AndreaYao, JenniferKoo, DavidHughes, Barbara

Clinical Trial 15,000$ BCNF International Evaluation of the 3rd Version of the SC Independence Measure

Respiratory Abboud Clinical Trial 825$ SmithKline Beecham Pharmaceuticals (Canada) Protocol 207499/041: A multicenter, open label extension study to evaluate the safety, tolerability and efficacy of oral ariflo (15 mg twice daily) in patients with chronic obstructive pulmonary disease (COPD)

Respiratory Abboud Clinical Trial 10,981$ Boehringer Ingelheim Ltd. 205.223 Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study).

Respiratory Abboud Grant 500$ Donations for Health Science Research Donations

Respiratory Atsuta Grant 25,000$ BC Lung: Fellowship Dr. Stefan Grzybowski Fellowship in Respiratory Medicine - Dr. Ryo Atsuta

Respiratory Ayas Grant 22,400$ BC Lung Project Grant The societal consequences of sleep apnea

Respiratory Ayas Grant 25,000$ CIHR: New Investigator Award (CIHR Scholarship) JBH-56261 Fellow: Ayas, Najib

Investigation of the diagnosis and treatment of sleep disordered breathing

Respiratory Ayas Grant 25,000$ BC Lung/CIHR Investigator (Fellow: Ayas, Najib) Investigation of the diagnosis and treatment of sleep disordered breathing

Respiratory Bai Clinical Trial 28,131$ Intermune Pharmaceuticals, Inc. An open-label study of the safety and efficacy of subcutaneous recombinant interferon gamma-1b (IFN-y1b) in patients with idiopathic pulmonary fibrosis

Respiratory Bai Grant 81,302$ CIHR: Operating Grant MOP-42537 Modulation of airway function by neurotrophic cytokines

Respiratory Chan-Yeung Grant 46,637$ CIHR: Operating Grant MOP-49479 Follow-up Study of a High Risk Birth Cohort Folllowing a Randomized Controlled Intervention Study on the Primary Prevention of Asthma.

Respiratory Duronio Contract 29,953$ WCB: Development Grant RS2002/03-DG13 Tendinosis and tendon regeneration: roles of apoptosis and insulin-like growth factor-l

Respiratory Duronio Grant 11,667$ H&SFBC: Research Fellowship (Kong, Jennifer) Cell Survival of Macrophages by Oxidized ldl is by a p13k Dependent Pathway in Atherosclerosis.

Respiratory Duronio Grant 22,000$ NCE/Protein Engineering: Research Pence P3 Post2

Respiratory Duronio Grant 22,500$ BC Lung: Project Grant Investigation of the P13-kinase Signalling Pathway in Human Lung Cancer as a Potential Mediator of Oncogenesis

Respiratory Duronio Grant 52,000$ Cancer Research Society: Research Grant Functions of Bad Controlled by Phorphorylation at a novel site

Respiratory Duronio Grant 100,000$ MSFHR: Senior Scholar Award 70(CI-2001):Vincent DURONIO

Key Signalling Pathways Controlling Survival and Death of Hemopoietic Cells

Respiratory Duronio Grant 118,867$ NCIC: Research 012332 Role of bad and mcl-1 in apoptosis, survival and cell differentiation

Respiratory Duronio Grant 119,354$ CIHR Operating Grant Cytokine regulated signalling pathways in inflammatory cells

Respiratory Fitzgerald Agreement 6,000$ Boehringer Ingelheim (Canada) Ltd. The Role of Screening Spirometry in the Early Identification of Smoking Associated Obstructive Lung Disease in an Adult Inner City Population

Respiratory Fitzgerald Clinical Trial 4,911$ Boehringer Ingelhein (Canada) Ltd. SAFE: Spiriva Assessment of FEV1. The Effect of Inhaled Tiotopium Bromide (18 mcg Once Daily) on the Change in FEV1 and Symptoms During Long-Term Treatment in Patients with COPD. A I yr Parallel Group Double-Blind Randomized Placebo Controlled Study.

Respiratory Fitzgerald Clinical Trial 6,700$ GlaxoSmithkline SAM40056 Protocol SAM40056: Randomized Double-Blind Double-Dummy Parallel Group Study of a Standard Dosing Regimen with Salmeterol/Fluticasone Combination 50/250ug bid (via the Diskhaler inhaler) vs a Symptom-Driven Variable Dosing Regimen with F….

Respiratory Fitzgerald Clinical Trial 29,865$ Hoffman-La Roche Ltd (Canada) Protocol BA 16631: Dose-Ranging Study of Ro 27-2441 in Patients With Persistent Asthma Not Treated With Inhaled Corticosteroid - Phase II

Respiratory Fitzgerald Clinical Trial 34,500$ GlaxoSmithkline PACE-IMT SAS40068 Protocol SAS40068: PACE-IMT 24 Week Multicentre Randomized Double-Blind Parallel Group Trial to Compare the Efficacy & Tolerability of Salmeterol/Fluticasone Propionate Diskus Combination (Advair) 50/100 mcg bid with Fluticasone Propionate





Respiratory Fitzgerald Clinical Trial 28,500$ Merck Frosst Canada & Co. 016-00 Protocol 016-00: Double-Blind Randomized Placebo- and Active-Controlled Multicenter Parallel-Group Proof-of-Concept Study of L-454560 in Patients with COPD

Respiratory Fitzgerald Contract 2,820$ Centers for Disease Control & Prevention 200-2001-00094, Task Order 0009

Enhanced surveillance to identify missed opportunities for TB prevention in foreign-born populations in the United States and Canada

Respiratory Fitzgerald Contract 20,255$ Centers for Disease Control and Prevention 200-2001-00094

CDC Tuberculosis Epidemiology Study Group

Respiratory Fitzgerald Contract 103,063$ Centers for Disease Control and Prevention Task Order #7, 200-2001-00085

Use of network analysis methods to characterise M. tuberculosis transmission patterns among women and other high risk populations

Respiratory Fitzgerald Grant 25,000$ BC Lung: Fellowship (Fellow: Numata, Yukka) Dr. W. Thurlbeck Fellowship in Respiratory Medicine

Respiratory Fitzgerald Grant 40,950$ CIHR/BC Lung Assn: Investigator (Fitzgerald, Mark) JBC-56221

Bringing evidence to the patient

Respiratory Fitzgerald Grant 41,944$ Vancouver Coastal Health Authority Salary: Clinical Trials Research Coordinator

Respiratory Fitzgerald Grant 42,000$ BC Lung/CIHR Investigator (Fitzgerald, Mark) Bringing evidence to the patient

Respiratory Fleetham Contract 40,390$ Various Pharmaceutical Companies Respiratory Division Education Fund

Respiratory Fleetham Grant 1,000$ Various Sources UBC Vancouver Hospital Respiratory Faculty Development Fund

Respiratory Fleetham Grant 27,000$ CIHR Univ-Ind: All CIHR Programs I-14909 (In collaboration with University Health Network)

Multi-centre Randomized Trial of Continuous Positive Airway Pressure for the Treatment of Heart Failure Patients with Central Sleep Apnea

Respiratory Fleetham Grant 25,000$ BC Lung: Fellowship (Fellow: Atsuta, Ryo) Dr. Stefan Grzybowski Fellowship in Respiratory Medicine - Dr. Ryo Atsuta

Respiratory Khalil Contract 63,034$ Glaxo Wellcome Inc (Now GLAXOSMITHKLINE) Transforming Growth Factor-beta in Pulmonary Airway and Parenchymal Remodelling

Respiratory Khalil Grant 60,000$ VHHSC Scientist Award: Nasreen Khalil Transforming Growth Factor Beta Regulation of Pulmonary Fibrosis and Airway Remodelling.

Respiratory Khalil Grant 5,000$ Newfoundland & Labrador Lung Association Distribution of TSP-1, CD36, Plasminogenn in idiopathic pulmonary fibrosis: an imminohistochemical study

Respiratory Khalil Grant 9,043$ Keryx Biopharmaceuticals Inc. Sulodexide(KRX-101) regulation of TGF-B1 mediated connective tissue synthesis by airway smooth muscle cells (ASMCs)

Respiratory Lam Clinical Trial 47,202$ Broncus Technologies, Inc. Feasibility Study of the Broncus Alair System for the treatment of asthma

Respiratory Lam Grant 48,953$ National Cancer Institute - USA Markers for Risk Assessment/Early Dectection of Lung and Breast Cancer

Respiratory Lam Grant 42,540$ National Institutes of Health - USA Partnership for Research in Optical Coherence Tomography

Respiratory Lam Grant 4,200,000$ Genome Canada & Genome BC Cancer Genomics: A Multi-Disciplinary Approach to the Large Scale High-Throughput Identification of Genes Involved in Early Stage Cancers

Respiratory Lam Grant 1,396,734$ National Cancer Institute - USA A Phase II of ACAPHA in Former Smokers with IEN.

Respiratory Lam Grant 6,700$ National Cancer Institute - USA The University of Texas SPORE in Lung Cancer

Respiratory Lam Grant 25,000$ BC Lung Association Novel Xenograft Models of Early Stage Human Lung Cancer and Preneoplastic Lesions

Respiratory Lam Grant 583,271$ National Cancer Institute - USA--Program Project Grant

Project 1: A Phase II Trial of Polyphenon E in Former Smokers with Bronchial Dysplasia

Respiratory Lam Clinical Trial 23,750$ Xillix Technologies, Corp. Onco-LIFE Endoscopic Light Source and Video Camera

Respiratory Lam Grant 304,872$ National Cancer Institute of Canada Identifying Molecular Targets for Prevention and Treatment of Lung Cancer

Respiratory Levy Clinical Trial 1,540$ Actelion Pharmaceuticals Canada Inc A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis

Respiratory Levy Clinical Trial 2,140$ GlaxoSmithKline An 18-week randomized,double-blind,placebo-controlled,multicenter study designed to compare treatment with Ariflo(cilomilast)to that with placebo for changes in ventilatory mechanics and function(both at rest and during exercise),as well

Respiratory Levy Clinical Trial 13,393$ Encysive, L.P. in collaboration with: Research Point Protocol FPH02 STRIDE II: Phase III Randomized Double-Blind Placebo-Ctonrolled Safety and Efficacy Study of Sitaxsentan Sodium Treatment with an Open-Label Bosentan Arm in Patients with Pulmonary Arterial Hypertension





Respiratory Levy Clinical Trial 17,214$ Encysive, L.P. in collaboration with: Research Point Protocol FPH02-X STRIDE II Extension: Open-Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium Treatment with a Bosentan Arm in Patients with Pulmonary Arterial Hypertension

Respiratory Levy Clinical Trial 19,290$ Encysive, L.P. Protocol FPH03 STRIDE III: Long-Term Open-label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension

Respiratory Levy Grant 29,164$ BC Lung: Project Grant Early detection of bronchiolitis obliterans following lung transplantation with CT imaging

Respiratory Ofulue Contract 84,699$ Roche Bioscience Efficacy of matrix metalloproteinase inhibitor in preventing cigarette smoke-induced emphysema.

Respiratory Pare Clinical Trial 259,647$ GlaxoSmithKline Develop and standardize accurate measurements of emphysema and airway wall dimensions inhuman lungs

Respiratory Pare Contract 151,913$ GlaxoSmithKline A two-year, multi-site family study to identify the genetic determinants associated with susceptibility to chronic obstructive pulmonary disease

Respiratory Pare Grant 1,300$ MSFHR: Doctoral Trainee Research Award # 54(02-1)BM Fellow: Despina FRANGOLIAS (Res/Travel)

Contribution of Genes other than CFTR Gene to Disease Severity in Cystic Fibrosis.

Respiratory Pare Grant 2,500$ MSFHR: Doctoral Trainee Research Award STPHD 129021 (Fellow: Wallace, Alison)

Role of alveolar macrophage proteinase genetic polymorphisms in the development of emphysema

Respiratory Pare Grant 3,500$ CIHR/PMRF: Fellowship Awards MFE-63469 Fellow: Camp, Patricia

Gender differences in chronic obstructive pulmonary disease

Respiratory Pare Grant 18,000$ MSFHR: Postdoctoral Trainee Fellowship STPDF 167021 ( Fellow: Mahmudi-Azer, Salahadding)

Mediator mobilization and release from neutrophil azurophillic granules in association with Asthma and COPD

Respiratory Pare Grant 79,656$ Ontario Genomics Institute Mapping and isolation of genes influencing severity of disease in cystic fibrosis

Respiratory Pare Grant 49,182$ Heart/Stroke Fdn Cda/CIHR: Strategic Training Initiatives PG-03-0191

IMPACT: Integrated and mentored pulmonary and cardiovascular training

Respiratory Pare Grant 49,400$ Parker B. Francis Fellowship in Pulmonary Research (Fellow: Mahmudi-Azer, Salahaddin)

Mediator mobilization and release from neutrophil azurophillic granules in association with Asthma and COPD

Respiratory Pare Grant 60,000$ American Thoracic Society, Inc Molecular mechanisms and genetic determinants of mediator mobilization and release from neutrophil azurophilic granules as it relates to COPD

Respiratory Pare Grant 61,531$ Various Sources Jacob Churg Distinguished Researchship Award

Respiratory Pare Grant 67,766$ MRC : Operating Grant MOP 37924 Human airway smooth muscle function and bronchial hyperresponsiveness

Respiratory Pare Grant 120,000$ MSFHR: Distinguished Scholar Award 60(CI-2001):Peter PARE

Molecular and Genetic Mechanisms of Obstructive Lung Disease

Respiratory Pare Grant 260,066$ CIHR/Strategic Training: Strategic Training Program Grant STR-63308

IMPACT: Integrated and mentored pulmonary and cardiovascular training

Respiratory Pare Grant 570,992$ CIHR: Operating Grant GEI-53960 Inflammatory Gene Hapiotypes and Susceptibility to Cardiac, Vascular and Pulmonary Disease.

Respiratory Road Clinical Trial 5,288$ Glaxo Smithkline Protocol 207499/180: 18 week Randomized Double-Blind Placebo-Controlled Multicenter Study Designed to Compare Treatment with Ariflo (Cilomilast) to That With Placebo For Changes in Ventilatory Mechanics & Function (both at rest and during….

Respiratory Road Clinical Trial 5,396$ Altana Pharma, Inc BY217/M2-107: A Comparison of Treatment with 250 ug Roflumilast vs 500 ug Roflumilast vs Placebo Over 24 Weeks in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Respiratory Road Clinical Trial 15,550$ AstraZeneca Canada Inc Protocol DC-039-0003: A Study in Canadian COPD Patients to Evaluate the Nature Treatment & Impact of COPD Exacerbation in Patients Who are Likely to Benefit From Treatment With Symbicort (budesonide/formoterol) Turbuhaler. An Open-Label…





Respiratory Road Clinical Trial 89,749$ Boehringer Ingelheim (Canada) Ltd Protocol 205.252: Randomized Double-Blind Double-Dummy Placebo & Active-Controlled Parallel Group Efficacy & Safety Comarison of 12 Week Treatment of 2 Doses (5ug(w actuations of 2.5ug) and 10ug (2 actuations of 5ug) of Tiotropium Inha...

Respiratory Road Clinical Trial 56,578$ Thera Technologies Inc. TH9507/II/COPD/003 A randomized double-blind, placebo controlled study of the safety and efficacy of two doses of TH9507 on physical performance, lean body mass and peripheral skeletal muscle strength in stable ambulatory COPD subjects

Respiratory Road Grant 10,000$ VHHSC: Interdisciplinary Grant Interdisciplinary approach to evaluating patients with suspected Mitochondrial Myopathy

Respiratory Road Grant 10,050$ CIHR: Randomized Controlled Trials (Clinical Trials) A randomised clinical trial to assess the efficacy of lung volume reduction surgery in the palliation of patients with chronic obstructive pulmonary disease

Respiratory Road Grant 22,500$ BC Lung: Project Grant Diaphragmatic Responses to Chronic Loading

Respiratory Ryan Grant 37,500$ ResMed/Vitalaire A Randomized Trial to Compare Polysomnography with Overnight Home Oximetry and Auto-CPAP for Diagnosis and Nasal CPAP Titration in Patients with a High Probability of Obstructive Sleep Apnea

Respiratory Sandford Grant 11,250$ MSFHR: Scholar Award C1-SCH-26(02-01) Fellow: Sandford, Andrew

Genetic modifiers of pulmonary disease severity in cystic fibrosis

Respiratory Sandford Grant 84,195$ CIHR: Operating Grant The role of macrophage protease polymorphisms in the development of emphysema

Respiratory Sandford Grant 90,000$ CCFF: Research Genetic Modifiers of Pulmonary Disease Severity in Cystic Fibrosis

Respiratory Sandford Grant 100,000$ Canada Research Chair: Tier II (CIHR) 950-01-2053 (Fellow: Sandford, Andrew)

Canada Research Chair" Dr. Andrew Sandford

Respiratory Sin Grant 32,500$ BC Lung: Investigator in collaboration with: St. Paul's Hospital (Fellow: Sin, Don)

BC Lung Association/St. Paul's Hospital Investigator Award: Dr. Don Sin

Respiratory Ward (Dimich) H Contract 102,040$ Worker's Compensation Board of British Columbia Impact of Western red cedar asthma on work, health and quality of life

Respiratory Ward (Dimich) H Grant 124,000$ BC Terminal Elevator Operators Assn Health and exposure assessment of grain elevator workers

Respiratory Ward (Dimich) H Grant 2,500$ Agriculture Canada Canadian Agricultural Injury Surveillance Program

Respiratory Ward (Dimich) H Grant 40,950$ CIHR/BC Lung Assn Investigator 40941: Helen Ward

Occupational health risks in the Health Care Industry

Respiratory Ward (Dimich) H Grant 42,000$ BC Lung/CIHR Investigator: Helen Ward Occupational health risks in the health care industryRespiratory Wilcox Clinical Trial 7,369$ Boehringer Ingelheim Pharmaceuticals Inc. Spriva Assessment of FEV1 (SAFE) The effect of inhaled tiotropium bromide (18mcg once daily)

on the change in FEV1 during long-term treatment in patients with COPD. A one-year parallel group, double-blind, randomised, placebo-controlled, st

Respiratory Wilcox Clinical Trial 13,522$ Boehringer Ingelheim Pharmaceuticals Inc. A Randomized,Double-Blind,Placebo-Controlled,study to investigate the Efficacy and Safety of 24 weeks of oral treatment with BIIL 284 in Adult (75mg,150mg) and Pediatric (75mg) Cystic Fibrosis Patients

Respiratory Wilcox Clinical Trial 29,943$ BCY LifeSciences Inc Effect of two doses (1000 vs 2000 mg/day) of aerosolised DCF 987 (Dextran 1) on pulmonary function and safety in adult patients with mild to moderate cystic fibrosis: A phase II, multicentre, randomised, double-blind, placebo-controlled, pa

Rheumatology Anis/ Esdaile Grant 36,120$ Canadian Arthritis Network (a Networks of Centres of Excellence)

Sensitivity to change and responsiveness of different indirect measures

Rheumatology Badii Grant 132,006$ Workers Compensation Board Prospective randomized double blind controlled trial of selective nerve root blockade in patients with acute or subacute sciatica

Rheumatology Blocka / Klinkhoff / Chalmers

Clinical Trial 9,402$ Hoffmann-La Roche A Randomized, Placebo-controlled, Double-blind, Multicentre Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis who have had an Inadequate Response to anti-TNFa Therapies

Rheumatology Chalmers/ Klinkhoff Clinical Trial 8,747$ Alexion Extension Study of h5G1.1-mAb in Rheumatoid Arthritis Patients Receiving Methotrexate or Leflunomide Who Participated in Study C01-004





Rheumatology Chalmers/ Klinkhoff Clinical Trial 32,000$ Bristol-Myers Squibb A Phase III, Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of BMS-188667 Administered Intravenously to Subjects with Active Rheumatoid Arthritis With or Without Medical Co-Morbidities Receiving Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Biologics Approved for RA

Rheumatology Esdaile Grant 2,000$ MSFHR: Doctoral Trainee Research Award 264-POPLehman, Allen

Development and Pilot Testing of a Novel Intervention to Ensure Optimal Support for Arthritis Patients

Rheumatology Esdaile Grant 17,500$ Arthritis Society: TAS00/0190,88062 UBC Rheumatic Disease Unit

Rheumatology Esdaile Grant 101,107$ CIHR Development of a model for the diagnosis of early knee osteoarthritis

Rheumatology Esdaile Grant 25,000$ CIHR New Emerging Team (NET) - Tooling up for early osteoarthritis: Measuring what matters

Rheumatology Esdaile Grant 5,606$ Canadian Arthritis Network (a Networks of Centres of Excellence)

Cost-effectiveness of anakinra compared to standard therapy and infliximab plus methotrexate for the treatment of rheumatoid arthritis

Rheumatology Greidanus/ Esdaile Grant 13,334$ Canadian Orthopaedics Foundation, VCHA Regulation of postsynaptic expression of GABAA receptors

Rheumatology Garbuz/ Esdaile Grant 54,528$ The Arthritis Society A randomized controlled trial of long vs short wait for primary total hip and knee arthroplasty

Rheumatology Kelsall/ Shojania Clinical Trial 28,340$ Aventis A Randomized, Placebo-controlled, Double-blind, Multicentre, Parallel group, Dose-Finding Study to Assess the Safety and Efficacy of Multiple Doses of HMR 3480 in Subjects with Rheumatoid Arthritis on a Stable Dose of Methotrexate

Rheumatology Klinkhoff/ Chalmers / Blocka

Clinical Trial 44,668$ Hoffman-La Roche A Randomized, Multifactorial, Double-Blind, Parallel-Group, Dose-Ranging Study of the Efficiacy and Safety of Rituximab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis

Rheumatology Klinkhoff/ Chalmers Clinical Trial 50,838$ Abbott A Phase III Multicentre Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Rheumatology Klinkhoff/ Chalmers Clinical Trial 20,808$ Abbott Continuation study of D2E7 in RA multi-centre continuation of the human anti-TNF antibody D2E7 administered as a subcutaneous injection in patients with rheumatoid arthritis

Rheumatology Kopec/ Badii Grant 7,499$ Workers Compensation Board Measuring Health Outcomes: An emphirical comparison of adaptive and standard questionnaires

Rheumatology Kopec/ Cibere Grant 138,098$ CIHR Population-clinical simulation model of osteoarthritis: development and applications

Rheumatology Kopec/ Esdaile Grant 29,491$ CIHR Physical activity and osteoarthritis: A case-control study

Rheumatology Kopec/ Esdaile Grant 17,312$ Canadian Arthritis Network (a Networks of Centres of Excellence)

Multi-level adaptive assessment of health-related quality of life: Integration of item response theory and preference-based management

Rheumatology Lacaille/ Esdaile Grant 77,625$ Canadian Arthritis Network (a Networks of Centres of Excellence)

Assessing the quality of care of rheumatoid arthritis (RA) at a population level

Rheumatology Lacaille/ Esdaile Grant 47,059$ Canadian Arthritis Network (a Networks of Centres of Excellence)

The effect of user fees on prescription drug utilization: Analysis of a longitudinal cohort of patients with rheumatoid arthritis

Rheumatology Lacaille/ Esdaile Grant 41,805$ The Arthritis Society Preventing work loss from inflammatory arthritis: program development and pilot testing

Rheumatology Lacaille Grant 8,744$ Canadian Arthritis Network (a Networks of Centres of Excellence)

Arthritis disability and participation in employment

TOTALS CDN 47,074,551$


ubc department of medicine page 183 annual report...

Documents